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Summary 
In this thesis, the work undertaken in an attempt to gain 
insight into the location of the binding site of bilirubin is 
described. 
The history, properties and biosynthesis of both bilirubin and 
albumin are reviewed in Chapter One. Chapter Two contains an account 
of the novel one-step method of labelling bilirubin of high yield 
and specific activity. In Chapter Three, the effect of light on 
bilirubin in the presence and absence of albumin, followed by the 
labelling of the albumin in an attempt to obtain information regarding 
the nature of the amino acid residues involved in the binding of 
bilirubin to albumin. Attachment of labelled bilirubin to albumin 
enabled the possible site on the latter to be followed during degrading 
procedures. Possible effect of this photo-induced binding on 
phototherapy is described. 
Chapter Four contains an account of the synthesis and binding 
studies of mesobilirubin. Fluorescence and spectroscopic methods 
are employed to determine the association constants of mesobilirubin 
and comparison with bilirubin made. The importance of the vinyl 
groups in bilirubin binding is cited and the possibility of mesobilirubin 
being a kernicteric pigment is hypothesized. 
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CHAPTER 1 
1. General Introduction 
1: 1 Historical Background 
The history of the bile pigments dates as far back as the second 
century A. D. when Galen associated jaundice with the presence of 
stones in the biliary tract. However, not until 1847, did Virchow 
demonstrate the association of bile pigment with haemoglobin. 
I 
He 
described the formation of bihrubin crystals (haematoidin) in blood 
extravasates. Tarchanoff 18742 showed that haemoglobin was converted 
to bilirubin. This then became the basis of theories on the mechanism 
of conversion of haemoglobin to bilirubin. Having synthesized haemin3 
and bi)irubin4, Hans Fischer was able to show that bilirubin was formed 
from haemin. 
5 
1: 2 Structure and Biosynthesis of Bile Pigments 
The bile pigments or bilinoids are open chain tetrapyrroles with 
the skeletal structure 3 (Figure 1). This basic structure is called 
bilin; by convention, (i) in the absence of specific information on 
the imino hydrogen location, the 22-H tautomer is drawn, and (ii) number 
20 is omitted; C-20 is a phantom atom that corresponds to the extra 
carbon atom that would be required to transform the bilinoid into a 
porphyrin ring (structure 1, Figure 1). Naturally occurring bilinoids 
have oxygen at the terminal positions, and are formally 1,19 - dihydroxy 
derivatives of bilin or 10,23 - dihydrobilin. As the natural compounds 
appear to be predominantly in the tautomeric bislactam form, they are 
commonly depicted in that form, but for convenience denoted by the 
6 
dihydroxy names. 
Biliverdin, mesobi]irubin including bilirubin (structure 4, Figure 1) 
are trivial names used to denote specific bile pigments. 1,19 - 
1. 
Dihydroxy derivatives of 10,23 - dihydrobilin are commonly called 
"(bili)aibins", and 1,19 - dihydroxy derivatives of bilin called 
"(bili)verdins". The configuration of ,6- substituents 
in rubins 
and verdins is denoted by reference to the corresponding protoporphyrin 
isomer that has the same sequence of substituents. Thus, the trivial 
name is followed by a Roman numeral (e. g. °IX), corresponding to that 
used to designate the isomeric type of the precursor porphyrin, and 
by a Greek letter (e. g. d.. ), indicating which one of the porphyrin 
meso-bridges ( dý ß, *A (F ) corresponds to the phantom C-20 carbon 
atom of the bilinoid. Following this nomenclature, bi]jubin - IX dk 
(structure 4) corresponds to the rtbin that is formed by cleavage of 
protoporphyrin- IX (structure 2) at the d meso bridge (Figure 1). 
Conventionally, however, the term "bilirubin" is used to specifically 
denote bilirubin - IXct . 
According to the sequence of the ,j- substituents on the pyrrole 
rings (positions 2,3,7,8,12,13,17,18) several isomeric types 
of porphyrins with the same elementary composition exist, and a "type" 
nomenclature, using Roman numerals, is used to distinguish these isomers. 
The protoporphyrin ring by convention corresponds to protoporphyrin - IX 
(structure 2 in Figure 1). The nature and sequence of the other 
substituents of porphyrins and the trivial name and type designation 
of the corresponding compound, is shown in Table 1. 
Depending on the configuration (Z or E) at the C-5, C-10 and C-15 
methene bridges , several geometrical isomers of bilins exist. Thus, 
biTirubin can occur in the form of four geometrical isomers (Figure 1): 
4Z 15Z - bilirubin (structure 4), 
4E, 15Z - bilirubin (structure 5), 
4Z, 15E - bilirubin (not shown), and 4E, 15E - bilirubin (structure 6). 
This thesis will concentrate on bibru. bin - IX d and the other 
members of the series are bi1rubin X111 o( and 111 o' and mesobiiirubin 
2. 
1 
1 
Figure 1 
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Trivial Names of Some Important Porphyrins Substituents at positions 
Name 2378 12 13 17 18 
Protoporphyrin - IX Me V Me pP Me Me 
V 
Protoporphyrin - III V Me Me pP Me Me V 
Protoporphyrin - XIII Me V Me pP Me V Me 
Uroporphyrin -IAPAPAPAp 
Uroporphyrin - III APAPPAAP 
Coproporphyrin - III Me P Me pP 
Me Me P 
Mesoporphyrin - IX Me Et Me pP 
Me Me Et 
HOOC COOH 
17 
H 
H 
IXd 
3. 
1X dk , X111 d and Ill of , which are fully discussed elsewhere. 
7'8 
Bilirubin (Figure 1) is an open tetrapyrrole, principally formed as 
a degradation product of ferroprotoporphyrin - 1X (heure). This molecule 
is an iron - containing tetrapyrrole macrocycle and plays a critical role 
in aerobic metabolism by reversibly binding oxygen in haemoglobin and 
myoglobin, and by serving as the active site in detoxification reactions 
catalysed by hemoprot ein enzymes. 
6 Heure may also have important regulatory 
functions in protein synthesis. Important cyclic tetrapyrroles in nature 
related to heure are chlorophylls, which contain magnesium and were found 
9,10 
to be derived from protoporphyrin - 1X, and vitamin B12, a corrinoid 
11,12 
derived from uroporphyrinogen - 111 (Figure 2). 
Whereas open tetrapyrroles have an important physiological role in 
algae by serving as prosthetic group of the photosynthetic biliproteins, 
bilirLbin in mammals merely is a waste product without any obvious function. 
However, the association of this pigment with yellow jaundice has 
interested, clinicians and investigators. BibYUbin, therefore, a potentially 
neurotoxic compound causes bilirubin encephalopathy and psychomotoric 
retardation in neonates with severe hyperbilirubinemia. These cytotoxic 
effects depend on its binding to intra - and extracellular "carrier" proteins 
and conversion into polar glycosides. This configuration is catalyzed by 
microsdmal UDP - glucuronyltransferase, an enzyme system that also plays a 
key role in detoxification and disposition of many other endogenous 
metabolites and xenobiotics. 
Bilirubin is formed by cleavage of the heme macrocycle almost 
exclusively at theo(- methene bridge so that viutually all the bilrubin 
formed has the 1X d configuration. This biTirubin formation therefore 
reflects the continuing turnover of heure and essential hemoproteins 
such as haemoglobin, myoglobin, cytochromes and other hemoprotein enzymes. 
The daily production in normal adults estimated by radiolabelled 
4. 
Figure 2 
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bilirubin13 or by measurements of endogenous carbon monoxide production14,15 
averages 250-350 mg per animal. Calculations of bilirubin production 
from carbon monoxide exhalation is based on the assumption that in normal 
individuals all heure degradation occurs by oxidative cleavage at a methene 
bridge and thus yields equimolar amounts of carbon monoxide and bilirubin. 
Carbon monoxide production, therefore, probably reflects total heure turnover 
in the body, whereas plasma bilirubin turnover reflects only the pigment 
fraction that enters the plasma prior to excretion and hence fails to 
account for bilirubin that is formed in the liver and directly excreted 
into bile. 16 These considerations probably explain why studies of plasma 
bilirubin turnover yield values for bilirubin production that are slightly 
lower than those calculated from carbon monoxide production. 
17 
A major portion of the heure in the body serves as the prosthetic 
group of haemoglobin and accounts for approximately 70% of the bilirubin 
excreted in humans. Variable amounts of heure are present in hemoprotein 
enzymes (e. g. cytochromes) which are essential in aerobic metabolism of all 
mammalian cells. Apart from the liver, these hemoproteins are so small, 
or their turnover rates so slow (e. g. myoglobin) that their contribution 
to the total bilirubin production is minute. Significant amounts of 
bilirubin are from the degradation of non-haemoglobin heure in the liver. 
Evidence for this non-erythroid source of bilirubin was first shown by using 
precursor glycine, 
18'19 
radiolabeled and the radioactivity examined in 
fecal stercobilin. The major peak of labelled stercobilin excretion 
corresponded to destruction of haemoglobin of senescent erythrccytes(after 
100 - 140 days), but between 10 to 20% of the excreted radiolabel in 
stercobilin appeared within the first few days after injection of the 
glycine. Production of this "early-labelled" bilirubin (ELB) begins 
within minutes after injection of the labelled heure precursor, reaches a 
peak value within one or three hours, and then declines asymptotically 
over a period of several days. 
20 
6. 
The existence of the two or more ELB components has been demonstrated 
using radiolabelled 
J'- 
aminolevulinic acid; this heure precursor is 
preferentially incorporated into hepatic heure rather than into hemoglobin 
of erythroblasts. 
21'23 
Recent observations are putting the hepatic 
contribution to total bilirutin formation from 10 to 20%24 to 23 to 37%1625. 
Thus the major contribution could be expected from cytochrome P450 as these 
hemoproteins incorporate at least 70% of total heure synthesized in the 
liver, 26 and treatment with xenobiotics that accelerate hepatic cytochrome 
P450 turnover correspondingly alter the shape and magnitude of ELB? 
7'28 
In addition, careful analysis of the initial EIS-component has revealed 
that the liver29 and erythroblasts 
30,31 
contain a small heure pool that exhibits 
aa turnover rate (60 - 90 minx) exceeding those of any known hemoproteins. 
It has been speculated that this pool may represent "free" or "unassigned" 
heure, which is in transit to the subcellular sites of hemoprotein synthesis 
and has important regulatory functions. 
34 
The erythropoietic contribution to ELB may increase when erythropoiesis 
is accelerated and/or abnormal (dyserythropoiesis); this is observed in 
hemolytic disorders such as iron deficiency anemia, megaloblastic anemia, 
lead intoxication, thallassemia and congenital erythropoietic porphyria. 
35,36 
A decreased ELB peak has been found in patients with aplastic anemia. 
37 
Haemoglobin heure is normally degraded to bilirutän in the mononuclear 
phagocytic cells (reticuloendothelial cells) of the spleen, bone marrow and 
liver in which senescent erythrocytes are sequestered. Free haemoglobin, 
on the other hand, released into the circulation by intravascular hemolysis, 
binds to haptoglobin, and this complex is taken up and degraded predominantly 
by parenchymal cells. 
38 Excess haemoglobin may be partially reabsorbed and 
degraded to bilirutin by the epithelial cells of the proximal convoluted 
tubule in the kidney. 
7. 
1: 3 Catabolism of haemoglobin 
It has been well-established that heure catabolism in man and other 
mammals normally results in nearly stoichiometric formation of carbon 
and requires molecular oxygen. Furthermore monoxide and bilirubin15 
39 
the conversion process is regiospecific40 with biliverdin as the intermediate, 
41 
such that all natural bile pigments have the 1X d configuration. 
Physiological heure degradation in mammals appears to be catalyzed 
by two enzyme systems, one microsomal, the other cytosolic. The initial 
reaction which is an oxidative attack on the d- methene bridge of heure, 
resulting in cleavage of the ring tetrapyrrole and formation of biliverdin, 
is catalyzed by heure oxygenase, a microsomal enzyme with the highest 
activity in the spleen, and other tissues such as the liver, and 
macrophages. 
42'43 
This enzyme is most active on "free" heure or heure 
loosely bound to protein (e. g. methemalbumtn) and fulfills the 
requirements of converting heure into equimolar amounts of carbon monoxide 
and bile pigment that has the 1X d configuration. 
The reaction catalyzed by heure oxygenase seems to be rate-limiting 
in the overall conversion of heure to bilirubin in vitro; the enzyme activity 
is inhibited by carbon monoxide and dependent on molecular oxygen and 
NADPH which is regenerated by NADPH - cytochrome C reductase. 
43 
Although heme. oxygenase uses the microsomal electron transport system, 
the enzyme is distinct from the drug - oxidizing enzyme system of the 
microsomes and it does not use cytochrome P450 as a terminal oxi, dase. 
44,45 
Microsomal heure oxygenase was purified from pig spleen; it has a molecular 
weight of approximately 32,000 and is free from heme. 
44 
Although the precise metabolic pathway of heure to biliverdin is 
still unclear, recent animal studies using 
1802 
and detailed analysis of 
in 
heure degradation/in vitro model systems has resulted in a substantial 
progress in the understanding of the pathway. It has been established 
8. 
that the terminal lactam oxygen atoms of bilirubin are derived from 
different 02 molecules, 
39,40 
that the initial reaction involves formation 
of an iron - 02 complex both in vivo and in vitro, 
46 
and that the apoprotein 
to which heure is attached during its degradation has a profound influence 
47 Current concepts on the regioselectivity of the cleavage reaction. 
-49 
of the heure oxygenase reaction45 developed from these studies and from 
analysis of heure degradation in a reconstituted microsomal heure oxygenase 
system can be summarized as follows (Figure 3). The heure is postulated 
to be dissociated from its apoprotein (e. g. globin) and transferred to the 
microsomal heure oxygenase apoprotein. The microsomal NADPH - dependent 
system reduces bound (ferric) heure to its ferrous form. The latter form then 
binds molecular oxygen by coordination to the iron and activation of the 
oxygen occurs; the mechanism although unclear is thought to involve electron 
transfer to the heure-oxygen complex in a way similar to that of the 
cytochrome P450 catalyzed hydroxylation. It is also assumed that in the 
heure-herne oxygenase substrate - enzyme complex heure is attracted to the 
protein such that the e, V and (f methene bridges are sterically 
hindered by the amino acid 
Oresidues 
from a bound oxygen molecule. 
48 
This 
arrangement is probably responsible for the preferential attack on the 
O( methene carbon by the activated oxygen species, resulting in formation 
of hydroxyheme. This intermediate would further react with two molecules 
of molecular oxygen to produce carbon monoxide and a ferric iron - biliverdin 
complex. This is followed by the subsequent release of iron, probably in 
the ferrous form; making this step a rate - determining one in the overall 
heure oxygenase - catalyzed reaction. 
the 
In mammals, /cytosolic enzyme, biliverdin reductase, abundant in the 
mammalian tissues, further reduces biliverdin to bilirubin in the presence 
50,51 
of NADPH. This enzyme displays a remarkable degree of isomer - and 
9. 
Figure 3 
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lo. 
substrate - specificity; unnatural, non - of isomers of bilverdin - 1X 
and biliverdin glucuronides are reduced at much slower rates or not 
52,53 
Mesobilirubin, which is formed in vitro by reduction of at all. 
the bilirubin vinyl groups to ethyl groups, is also derived biogenetically 
from bilirubin. 
54-58 
The brain tissue was shown to reduce bilirubin to 
mesobilirubin, in vitro, 
59 
which could possibly occur after non - bound 
unconjugated bilirubin has crossed the blood - brain barrier. 
Experimental evidence has shown that deeply jaundiced individuals 
have no bilirubin in their cerebral tissues. 
60 
1: 4 Metabolism of bilirubin and mesobilirubin 
1: 4: 1. Transport in plasma 
From the sites of its formation bilirubin is transported in the 
plasma tightly bound to albumin and to ligandin in the liver. At 
physiological pH only minute amounts of unconjugated bilirubin are 
soluble in protein - free aqueous solutions which have been estimated 
from titration studies to be 7x 10-9 M, at 37'x, at pH 7.461 and 
2x 10-7 M (0.006 mg%) at pH 7.4, at 25'c ionic strength 0.10M. 
62 
The protein, albumin, contains one high-affinity binding site with an 
estimated affinity constant (Ka) of 1.4 x 108 M-1 in purified human 
albumin (1.2 x 108M-1 in albumin of Gunn rat plasma). 
64 
Since the 
concentration of unbound bilirubin is usually very low approximately 
10-8 M to 10-9M, it is postulated that the cytotoxicity of bilirubin 
is directly proportional to the unbound bilirubin, thus Riving binding 
proteins an additionalfunction of detoxification. Many endogenous 
metabolites such as sulfisoxazole65 and salicylate66 are known to lower the 
bilirubin binding capacity in a whole serum resulting in a concomitant 
escape of unbound pigment from the vascular compartment. 
65,66 Lo chain 
fatty acids are transported bound to albumin and at a concentration range 
11. 
beyond 4: 1 with regard to albumin, they displace bilirubin from the 
high-affinity binding site. 
67 Thus elevated free fatty acid concentrations 
in babies receiving parenteral nourishment with fat emulsion or breast- 
fed infants may result in an increased concentration of unbound bilirubin 
and development of kernicterus. 
68,69 
Observations suggest that the interaction of bilirubin with albumin 
is one of the most important determinants for regulating the blood level 
of bilirubin and consequently for the pattern of pigment distribution 
among the various body compartments. This has been borne out in studies 
of unconjugated hyperbilirubinemia in man (Crigler-Najjer syndrome) and 
rat (Gunn strain). 
70 
However, bilirubin in the circulation is normally 
rapidly cleared by the liver. It is also generally accepted that 
bilirubin is separated from the carrier albumin prior to its uptake in 
the liver cell. 
71,72 
This hepatic uptake of bilirubin, which is 
speculated to be carrier-mediated and shared by other organic anions 
including bromosulphophthalein and indccyanine green, 
73 
greatly exceeds 
the overall transport maximum; thus making it a non rate-limiting step 
in hepatic bilirubin excretion. 
73 
The true mechanism of the hepatic 
uptake is a matter of speculation but there is growing evidence of the 
existence of bilirubin binding proteins inside the liver. The most 
abundant one- is ligardin. 
74 
Ligardin binds a variety of compounds 
including bilirubin, heure, steroids, bromosulphophthalein and carcinogens. 
Another protein corresponds to Z protein or fatty acid binding protein 
(FABP). 
74 
This protein, although it binds bilirubin less strongly 
than ligarriin, is principally involved with free fatty acid transport. 
75 
The affinity constant for bilirubin of purified rat ligandin (106M-1) 
is considerably less than that of ligandin in unfractionated rat liver 
cytosol (109M-1 ) which suggest that some cytoplasmic property or 
12. 
constituent(s), perhaps glutathione, 
76 
might be required for the 
preservation of intact binding of bilirubin to ligandin. Rat ligandin 
is a dimer (molecular weight 46000) composed of two nonidentical 
subunits that may be responsible for different catalytic and binding 
functions. 
77 
unctions. 
77 
Its physiological role, like albumin in plasma, is 
solubilization, storage and detoxification of bilirubin; and influencing 
a 
the net hepatic uptake a concept supported by recent studies using/multiple 
indicator dilution technique, which permits individual measurement of 
influx and efflux. 
78 
Physiologic studies on the blood-brain barrier have not provided 
a precise definition and the concept remains functionally ambiguous. 
In general therefore, it is useful to consider the blood-brain barrier 
in relation to the physical-chemical properties of specific types of 
compounds. The blood-brain barrier plays a central role in the 
pathogenesis of bilirubin encephalopathy but factors governing the 
entry of bilirubin into the central nervous system have long been a 
matter of speculation. 
79 
Bilirubin is a highly lipid-soluble, nonpolar 
molecule which easily crosses biologic membranes, except when bound to 
albumin. It was shown that the newborn and adult animals did not differ 
fundamentally in the functional characteristics of the blood-brain 
barrier for bilirubin. Unbound pigment moves across the barrier rapidly 
in either direction thus providing strong evidence against the concept 
of "immaturity" of the blood-brain barrier for bilirubin and therefore, 
other explanations are required to account for the almost exclusive 
occurrence of the bilirubin encephalopathy in newborn infants. 
79 
However, experimental evidence shows that the kernicteric pigment has 
the properties of solid mesobilirubin. Mesobilirubin injected 
intracerebrally in newborn kittens stained the tissue a bright canary 
yellow. 
80 
Very few studies have been done on the association of 
13 
mesobilirubin with known carrier proteins, but albumin does bind 
mesobilirubin81 and available methods do not differentiate the pigment from 
bilirubin in serum. 
82 
1: 4: 2. Transport Vehicles 
Within the plasma exists the "transport milieu" that is the mobile 
milieu in which substances and biological units are contained, and which, 
through transitory bindings, serve the transport processes as such. 
The vehicles are components of the transport milieu which always have 
the longer biological half-life. Two transport systems do exist: 
"the macro-distance transport" - the motive power of which is caused by 
the pumping of the heart and the "micro distance transport" - which 
exists within fixed membranes or within the cells themselves. 
83 
Although 
exceptionally complicated only albumin which is 42 gm/litre in blood 
serum, is concerned as a binder in the macro-distance transport of bilirubin. 
Albumin contains four similar subunits which are covalently joined 
to make a single polypeptide chain and Peters84 recently proposed a 
four domain model based especially on large fragments which retained 
structural and functional properties. The amino acid sequence and 
disulphide bridges of serum albumin reveal a pattern of loops that 
indicate how the molecule evolved from a pattern of about seventy seven 
residues by four fold tandem gene duplication and one deletion, to give 
a protein of about 585 residues (Figure 4). 
84 
The sequence and disulphide bridges as shown in Figure 5, reveal 
a pattern of loops and connecting segments that repeat three times. 
The three major repeat units, consisting of two large double loops 
separated by a small double loop, corresponding approximately to 
residues 1-190,191-382, and 383-585. One exception to the pattern is 
the first loop which is missing cysteine residues that should close the 
large loop at 8 and 54. The bridge was probably lost during evolution. 
14. 
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16. 
Thus the protein may be considered to contain nine domains corresponding 
to the six large and three double loops. 
85 This repetitive nature of 
the albumin structure, the high helical content of 54-68%, and the 
restrictions imposed by the double cysteine bridges greatly simplify 
consideration of three dimensional models. 
Crude commercial preparations of albumin are heterogenous due to 
impurities such as 41, - globulins, enzymes, dimers, mercaptalbumin and 
im some cases abnormal albumins. This heterogeneity can be avoided by 
using crystalline or chromatographically purified albumin. The most 
studied cause of heterogeneity is isomerisation (Figure 6). Essentially 
this isomerisation exists from the simple, reversible expansion to 
irreversible disulphide rearrangment. At pH 5-7, the normal, N form 
predominates and below pH 4 appears the F, for fast-migrating form which 
is somewhat expanded; below pH 3 the molecule expands further to expose 
most tyrosines and other hydrophobic residues to the solvent. At higher 
pH values, near pH 8, particularly in the presence of calcium ions, a 
different expansion, with increased accessibility of hydrogen atoms 
for exchange, increased mobility of the thiol group and the slight loss 
of helix, produces the B form. The B form, is however, readily 
reversible. Above pH8 a slow transformation to the A form occurs. 
This A form is the opposite of the F form, described above, that 
is, slightly slower migrating that the N form on electrophoresis (pI of 
5.45 compared to 5.24). 
86 
Disulphide bond rearrangement is involved 
since the A transformation is accelerated by small amounts of thiol 
compounds and suppressed by alkylating agents such as iodoacetamide. 
The change to the A form becomes irreversible near pH 10. However, 
the A form disappears faster than the normal or N form in vivo and 
suggests that it may be an intermediate in albumin degradation. 
87 
The present knowledge of the structures of human and bovine albumins 
17. 
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Isomeric forms of albumin observed at different pH values. 
18. 
is accredited to Brown and his colleagues88 and Meloun's group. 
89 
Both 
teams noted the regular occurrence of adjacent Cys-Cys sequences which 
are the basis of the repeating loop structure. The loops are numbered 
sequentially from 1 to 9 rather than by domains; thus, loops 1 -3,4 -6 
and 7-9 are domains I, II, and III respectively (Figure 5). 
The secondary structure of albumin was estimated by circular 
dichroism (CD), predictions from the amino acid sequence and model 
building. The total of 50 - 55% d- helix and 15 - 18% 13 - sheet 
derived from optical measurements, approximates the predicted total from 
amino acid sequence of 46% d and 16%, S for bovine albumin. 
The stability and flexibility of albumin in the face of conditions 
which would denature many other proteins is attributed to the loop structure. 
An isolated fragment loops 7-9 of the bovine protein shows the strong 
primary site for palmitate and an amino terminal fragment. Loops 1 -5, 
binds bilirubin as strongly as does the native albumin. 
90 
Similarly, at 
least six antigenic sites appear to be preserved in fragments some as 
small as one loop in size. 
91,92 The autonomy of local regions is not 
dependent solely on S-S bridging, since even isolated frgaments can 
ref old to the native disulphide pattern after complete reduction of 
disulphides; as attested by the return of antigenic sites91 and of 
native circular dichroic pattern and fatty acid binding. 
92 The return 
to the native structure is however slower in the albumin than in the 
fragments after reduction. Hence the refolding probably initiates in 
the local regions, so that the individual loops form their S -'S bonds 
rapidly and semi-independently, preventing the occurrence of unnatural 
S --S bond between loops or the intertwining of strands through loop 
openings. That the helix appears before palmitate binding ability returns 
is in agreement with the concept that secondary structure forms before 
tertiary structure. 
92 
19. 
Expansion at acid or alkaline pH, for example, is probably a 
repulsion of loops as salt bridges are broken. Formation of the A 
isomer above pH 8 is believe to involve the single thiol at C ys34 as a 
catalyst to effect an interchange between two disulphide bonds depicted 
in Figure 7. 
Figure 7. 
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Diagram of a possible base-catalysed disulphide interchange model, 
showing how the thiol group may effect the interchange of two S-S 
bonds yet remain itself unchanged. 
Taken from Ref. (92) 
This interchange has been shown to occur only in the first domain. 
The N- terminal position of the albumin molecule is relatively compact 
compared to the C- terminal region. Further evidence suggests that 
the C- terminal portion unfolds more extensively than does the N- 
terminal portion during the N-F transformation. 
93 Much of the 
compactness of the N- terminal is due to the hydrophobicity and the 
numerous aromatic residues of loop 3. The tryptophan in loop 3 (bovine 
albumin) the analogous residue is absent in human albumin, fluoresces 
more strongly than the one in loop 4.94 
On the basis of the current information the locations of sites 
on the albumin molecule are divided into the following categories: 
a) the hydrophobic, non-covalent sites for (1) primary long chain fatty 
20. 
acids, (2) bilirubin and certain drugs, (3) indole compounds and certain 
other drugs; 
(b) covalent attachment sites for organic ligands including the thiol 
group; 
(c) chelation sites for divalent metals, see Figure 8. 
(d) sites for organic dyes. The binding of the dyes is useful for 
physico-chemical, medical or analytical studies. The association constants 
decrease from 1.7 x 107 to 2.8 x 104 M-1 for the compounds sulphobromophthalein 
(BSP)95, bromophenol blue96, Evans blue97, bromocresol green98, methyl 
orange 
99 
and phenol red. 
100 Thus the specificity for certain dyes is 
used for albumin assays in the plasma. 
Figure 8 
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Model of principal ligard binding sites of albumin. 
The assay of albumin bromocresol green gives linear results and is free 
from interferences, 
101,102 
unlike the separation from globulins and 
subsequent measurement by general methods of proteins. 
1: 4: 3. In vitro and In vivo Bilirubin-Albumin Binding Studies: 
A number of methods have been used to measure the binding of 
108 
bilirubin to albumin, such as quenching protein fluorescence, circular 
21. 
CalHSA) ASPRIN 
dichroism, 
104 
ultrafiltration, 
105 
ultracentrifugation, 
106 
dialysis, 
107 
electrophoresis, 
107 
gel filtration, 
108 
electron absorption spectro- 
photometry, 
103,109 
spectrofluorimetry, 
103,109 
spectropolarimetry, 
110 
competitive binding to calcium carbonate 
ill 
and affinity chromatography 
on agarose - albumin polymers. 
112 
This binding is reversible and it is accompanied by development of 
a characteristic absorption spectrum (X max 460 mm at pH 7.4), 
103 
appearance of optical activity in the visible light region, 
103 
enhanced 
circular dichroism, 
104 
development of bilirubin fluorescence, 
103 
and pro- 
tection of the pigment from photochemical autoxidative, and enzymatic 
degradation. 
113 
There is little agreement on the binding capacity of serum albumin 
for bilirubin and the size of the corresponding association constants. 
Despite all the work done in the binding of bilirubin to albumin, 
investigations have tended to be obfuscated and bedeviled by the physical 
and chemical instability of bilirubin in aqueous solutions and its 
tendency to adhere to many surfaces, including glass. This, therefore, 
calls for critical evaluation of the techniques used in the binding studies 
before conclusions can be drawn. Much of the disagreement lies around 
the role of crude and impure albumin and bilirubin preparations; added 
to this is the difficulty in measuring unbound pigment at low bilirubin- 
albumin ratios. There is, however, a general agreement that pure 
albumin binds at least one molecule of bilirubin tightly. 
Most of the methods used for in vitro binding studies of bilirubin 
to albumin have certain anomalies and of the spectroscopic methods that 
have been used the fluorimetric technique103 has the greatest appeal in 
terms of simplicity, sensitivity, and realibility. The only chemical 
method that has been applied is the peroxidase method* 
64,114 This 
technique evolved from thecbservation that bilirubin is oxidized by 
22. 
hydrogen peroxide or ethyl hydroperoxide in the presence of peroxidase 
much faster when albumin is absent than when it is present. 
113,114 
It 
is based on the assumptions that the initial velocity of the enzymatic 
oxidation in the presence of albumin is slower than the dissociation of 
bilirubin from albumin (i. e. rate limiting) and directly proportional 
to the concentration of unbound bilirubin. 
64 Since the method requires 
measuring the rate of oxidation of bilirubin in the presence and absence 
of albumin, difficulties may be experienced at physiological pH because 
of the instability of bilirubin in the albumin-free solutions. 
114 
Association constants obtained by the peroxidase method tend to be a 
magnitude higher than those obtained by other methods. 
For purified human albumin the association constant is in the range 
7-8 -l 10 10 M This indicates that the concentration of unbound bilirubin 
in a solution containing bilirubin and albumin at a ratio of 1: 1 will be 
less than 10-6 - 10-7 M. For a bilirubin-albumin ratio of 1: 2, the 
unbound bilirubin concentration will not exceed 10-7 - 10-8 M, and for 
a solution containing 0.60 mM (3.99g%) albumin and 0.17mM (lOmg%) 
bilirubin (typical values for rather jaundiced serum) the "free" bilirubin 
would be approximately 4x 10-8 -4x 16-9 M. 
115 The variation with 
temperature of bilirubin binding affinity to human serum albumin seems 
to indicate that the binding forces are enthalpic and, therefore, 
predominantly of an electrostatic nature. 
Only purified human adult albumin will be dealt with in this thesis. 
Binding studies in vivo, i. e. in the presence of serum have been done 
using a more rapid micromethod for measuring the reserve albumin binding 
capacity with the dye, 2- (4 - hydroxybenzene azo) benzoic acid (HBABA). 
This method has been used in infants who developed kernicterus and were 
shown to possess no or low binding capacity. 
116 A more common method for 
the determination of unconjugated serum bilirubin has been carried out 
23. 
using chromatbgr4iiy on Sephadex G-25. Data obtained by this method 
indicates that the amount of bilirubin, both in vivo and in vitro, 
varies directly with the level of total bilirubin. 
Using a dialysis technique purified fetal human albumin prepared 
from umbilical cord blood was shown to have a greater affinity for 
bilirubin than adult human albumin. 
117 
The affinity of albumin for 
bilirubin is dependent on the medium, and the effective binding capacity of 
albumin for bilirubin can be reduced by substances that compete with 
bilirubin for binding. The binding capacities of purified human adult 
albumin in buffer and the albumin in adult human serum were shown by 
circular dichroism, peroxidase and chromatography on Sephadex G-25 
to be identica1.114,118,119 However, measurements with an indirect 
fluorimetric method do not support the above conclusion, but instead 
indicate that the capacity of the albumin in adult serum is about twice 
the capacity of the purified protein. 
120 
The following tentative 
conclusions can be drawn from studies published so far: (a) the presence 
of normal serum has little effect on the binding capacity or affinity of 
albumin for bilirubin, except perhaps to increase the latter. 
(b) Unidentified factors may occur in neonatal serum that 
decrease the effective capacity of the first high affinity binding site. 
The binding affinity of albumin for bilirubin is decreased by 
the presence of dimethylsulphoxide, 
117 
and varies with ionic strength. 
118 
Increase in temperature tends to decrease the affinity. Although circular 
dichroism and fluorescence spectra of bilirubin-albumin complexes are pH 
dependent 
104,109,118 
the binding characteristics of the primary binding 
site of serum albumin appear to be independent of pH over the range 
pH 7-9.119,128 Nevertheless, acidosis in vivo favours a shift from 
serum albumin to fat. 
24. 
In human serum albumin the high-affinity site seems to be a hydrophobic 
crevice located about 28A° from the single tryptophan residue, 
103 
and with 
arginine, tyrosine, histidine, and lysine residues in the more immediate 
vicinity. 
122-124 
Little else is known about the geography of the binding 
site except that its chirality at physiological pH is not the same for 
albumins from different animals. 
103,118 
Bilirubin conjugates 
125 
and 
bilirubin dimethyl ester125 bind to albumin and bilirubin covalently 
anchored to a polymer support via its propionic acid side chains binds 
albumin. 
112,126 Quantitative studies have shown that mesobilirubin also 
binds to albumin. 
81 
Hydrophobic interactions, 
ill 
and perhaps hydrogen 
bonding between the lactam groups of bilirubin and amine groups of the 
protein127 seem to be more important. The change from the methene to 
methylene bridge (position 10, Figure 1 structure 3) in the tetrapyrrole 
pigment gives biliverdin and the latter forms a non-ultrafiltrable complex 
with albumin 
128 
There is also strong evidence that the carboxyl groups 
of bilirubin, in the serum albumin-bilirubin complex, are oriented towards 
the aqueous phase of the medium. Although the conformation of the bound 
pigment (bilirubin) is not known, it may be inappropriate and misleading 
to consider bilirubin as a typical "organic anion" with respect to its 
complexation to albumin, at least at the high affinity site. Recent 
studies, however, point out that bilirubin acid releases two protons on 
binding to albumin129 which is stoichiometrically equivalent to binding 
bilirubin dianion. 
The binding of bilirubin has a marked effect on its chemical reactivity. 
Whilst it is known that bilirubin is chemically unstable in water, the 
pigment is relatively stable in chloroform or when it is bound to albumin. 
The reason for this stabilising effect due to the protein is not known. 
Probably the pigment assumes a stable, introverted, intramolecularly 
25. 
hydrogen-bonded structure when bound, or perhaps its sensitive and 
vulnerable parts, especially the central bridge, are protected by the 
lipophilic environment of the albumin interior. This lipophilic 
environment of the albumin interior binding site is known to be on or 
around lysine - 240 of the albumin molecule. 
124 
1.5 Photochemistry of Bilirubin 
The realisation of yellow jaundice was first by Galen and dates back 
as far as Hippocratic medicine (460 - 370 B. C. ). Thus for centuries the 
view of jaundice continued and it was not until 1807 when Thenard studied 
the yellow pigment of bile isolated from bovine biliary calculi. 
130 It 
was in the hope of treating neonatal jaundice by phototherapy that 
stimulated a sudden and continued interest of the photochemistry of 5,15 - 
biladienes, bilirubin IX o in particular. 
Bilirubin in water or common organic solvents at room temperature does 
not fluoresces 
103 
On the other hand, solutions of bilirubin in which the 
pigment is solubilized with detergents131 or by binding to serum albumin103,118 
and basic solutions of bilirubin in organic solvents, (e. g., 1% NH4OH - 
MeoH, 10% triethylamine-chloroform) do show a distinct fluorescence that 
is clearly visible and is most intense at about 510-530.118,131 Clinically, 
this has been of great importance for the determination of the reserve binding 
capacity of newborn serums. 
In the presence of oxygen, bilirubin has been known to photosensitize 
the formation of singlet oxygen. 
122,134 The following sequence of reactions 
is thought to occur: 
Bilirubin (So) Bilirubin (Sl 
Bilirubin (S1) Bilirubin (T1) 
Bilirubin (T1) 02(3 : ýj6) ) Bilirubin (So) + 02 (1/ý ) 
26. 
1: 5: 1. Photooxidation 
One of the major problems met by scientists working with bilirubin 
is its photooxidation and photodegradation on exposure to light. The 
rate of decomposition however, depends on several factors: the physical 
state of the pigment, its concentration, its environment, the oxygen 
concentration, and the wavelength and intensity of the ambient light. 
Photodegradation occurs slowly in the presence of albumin and much 
faster in dilute solutions in organic solvents and this is under both 
aerobic and anaerobic conditions. 
135 
So far photooxidation of bilirubin 
produces predominatly biliverdin as the product although this reaction 
depends on the conditions employed. High concentrations of the starting 
material and nonpolar solvents appear to favour biliverdin formation, and, 
since the leaction is probably a free-radical process it also should be 
favoured by binding of bilirubin to albumin. It has however not been 
established whether oxygen is required for the photooxidation of bilirubin 
to biliverdin. The photooxidation of bilirubin often competes with its 
photooxygenation and the major products in the latter reaction have been 
shown to be the mono- and dipyrrolic structures (Figure 9) 
136,137 
The predominant modes of attack of singlet oxygen on bilirubin are 
evidently 1,4 - addition across the pyrrole rings and 1,2 - addition to 
the bridging, double bonds as indicated on (Figure 10). The intermediate 
adducts are probably transformed into final products by thermal reactions. 
The intermediate adducts have been isolated from the photooxidation of 
bilirubin - albumin solutions, 
138 
and the partially characterized pigments 
isolated in low yield by Berry et al139 from an irradiated solution of 
bilirubin in chloroform may be related to these obligatory dioxetan 
intermediates. The mechanism of the photooxidation of protein - bound 
or complexed bilirubin has not been established. 
27. 
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1: 5: 2. Photoproduct formation 
Bilirubin in chloroform absorbs at approximately 450 nm but when 
solutions of it in buffer (pH 7.4 or 8.5) aqueous albumin or rat serum 
are irradiated for six hours with a 400 - watt high pressure mercury 
lamp with UV filter, the pigment is partially converted to a compound 
with an absorption maximum (in chloroform) at 442-444nm. The yellow 
pigment is probably identical with the unidentified compound which was 
isolated by ultrafiltration from irradiated solutions of bilirubin in 
aqueous albumin. 
140 
This photoproduct has the same properties as the 
natural pigment, that is it dissolves in chloroform and can be 
chromatographed on polyamide layers. However, unlike the natural pigment, 
it is unstable on silica gel layers, it is extractable from chloroform 
solutions into 0.1M aqueous sodium hydrogen carbonate, and fails to give 
diazo and pentdyopont tests. This same pigment has not been detected 
in the serum of normal or bile-duct ligated Gunn rats following prolonged 
exposure of the animals to illumination. 
141 
1: 5: 3. Photoaddition and Photoisomerisation 
Exposure of bilirubin IX o( to illumination in the presence of 
alcohols, or thiols leads to a stereospecific addition to the exo-vinyl 
group (Figure 11). 
142 
This reaction is thought to proceed via a prototropically rearranged 
intermediate (II) and to constitute a rare example of photochemically 
induced ionic addition to a vinyl group. Methanol and 2-mercaptoethanol 
are representatives of the two classes of adducts that have been used, 
for these reactions which have to be carried out under inert atmosphere 
to avoid the more facile photooxidation of the starting material and 
products. 
Photoaddition to the endo-vinyl group of a rubin also in chloroform 
28. 
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Interconverston of biltrubi. n isomers by Di. sproportlonation, 
has been observed using a large excess of thiol in the presence of a 
disulphide and a rubin without an exo-vinyl substituent. (IV--4V, Figure 11). 
Irradication of bilirubin IX d in deoxygenated aqueous buffer (pH 
7.4 - 8.5) gives the isomers bilirubin III (A and bilirubin XIII a* . 
This is a reversible reaction which is a counterpart of the oxygen-initiated 
free-radical disproportionation. The same reaction occurs in chloroform 
and chloroform - methanol although more slowly. 
143 
In sodium hydroxide, 
(0.1M) or dimethylsulphoxide, anionic and neutral detergents, or if the 
bilirubin is bound to serum albumin in aqueous solution, the reaction does 
not take place or occurs at an extremely slow rate. However, addition of 
acid to bilirubin IX c4 leads to a mixture containing all the isomers. 
144,145 
Thus mixtures of symmetrically substituted rubins can be converted to mixtures 
of unsymmetrical compounds (Figure 12). 
The mechanism resulting from acid-catalysed isomerisation, depending 
on which side of the C-10 bridge electrophilic attack takes place will give 
the dipyrrolic fragments as shown in (Figure 12). In bilirubin IX ° 
the rate of proton attack at -C-9 and C -11 are similar because these positions 
are virtually identical and cleavage of the molecule occurs randomly at 
either side of the bridge. Mixing and recombination of the fragments is 
also more or less random in concentrated solutions (5 mg/mL) at room 
temperature. 
, 
Hence the product contains a distribution of isomers that is 
almost statistically random. 
Treatment of bilirubin IX o& with hydrochloric acid for one minute gave 
a mixture (87% yield) containing 23% bilirubin III, 49% bilirubin IX o( , 
and 29% bilirubin XIII o(, which is close to the theoretical distribution 
lll of 1: 2: 1 for a completely random cleavage and recombination process, 
The slight preponderance of XIII Q( over III cA- is perhaps due to the 
destabilizing effect of the vinyl groups in the latter. The recovery of 
30. 
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33. 
bilirubin is inversely proportional to the time of treatment with acid 
and so does the deviation from the theoretical distribution resulting in 
an increased proportion of bilirubin XIII d. The rate of acid-catalysed 
isomerisation decreases with the dilution of the pigment and is low with 
weaker acids such as acetic acid. 
144 
Bilirubin IX cI4, treated with 
p-tolu2nesulphonic acid in chloroform does not isomerise. 
145 
Free - radical isomerisation which is different from acid-catalysed 
process in that it is slower, occurs in water or boiling pyridine in the 
dark and does not take place if oxygen is rigorously excluded from the 
solution. Thus the overall isomerisation reaction depicted on (Figure 14) 
takes place when bilirubin IX c& is warmed in moderately basic aqueous 
4olutions (pH 7.4-12). This reaction which is thought to be initiated 
by oxygen, 
146 is inhibited by ascorbic acid, glutathione and thiourea 
and can be promoted even in the absence of oxygen by benzoyl peroxide, 
iodine, nitric acid or light. Although the mechanism is unclear, one 
suggestion is that initiation leads to formation of resonance stabilized 
dipyrrylmethene radicals, 
X' + A-CH2 -B ---ý AX + 3CH2' 
X' + A-CH2 -B BX + AICH2' 
which can then reect with other pigment molecules, 
B-CH 2 + A-CH 2 -B --ý B-CH-B + 2 2 A-CH 
A-CH2' + A-CH2 -B A-CH2-A + B-CH2' 
by a bimolecular substitution reaction (Figure 12) to give isomers. 
147 
The free-radical isomerisation of bilirubin is dependent on concentration, 
pH, and solvent. In very dilute solutions (2.1 uM) in water, the 
reaction is very slow and loss of pigment and autoxidation predominates. 
The reaction does not occur in neutral organic solvents such as chloroform 
and ceases when the pigment is bound to albumin in aqueous solutions. 
146 
34. 
It is this reaction which is likely responsible for the occurrence of 
bilirubin III C% and XIIId in commercial preparations. 
Because of its low solubility in water (7nM) bilirubin has been 
solubilized in water by surfactants (e. g. sodium deoxycholate) giving 
clear micellar concentrations. 
148 
Complete solubilization occurs at 
surfactant concentrations greater than the critical micelle concentration, 
i. e. 72.4 mM for sodium deoxycholate and anionic (bile acid salts, sodium 
dodecyl sulphate), neutral (Tween 20, Triton X- 100) and cationic 
(cetyltrimethylammonium bromide, cetylpiyridinium chloride) detergents 
can be used. There is also an increasing interest in the use of micellar 
systems to simulate some of the electrostatic and hydrophobic environments 
found in biological systems in order to elucidate their effects on the 
kinetics and mechanism of photoreactions. 
149 
Thus, it has been 
demonstrated that singlet oxygen, produced in an aqueous solution, can 
penetrate into the interior of anionic or cationic micelles and oxidize 
substrates dissolved therein; 
150,151 
singlet oxygen can also be generated 
inside a micelle and diffuse through the aqueous medium to a different 
micelle. Irradiation of bilirubin or hematoporphyrin in the presence 
or absence of detergents causes the photooxidation of the pigments. 
152 
In the absence of dispersed micelles the photooxidation is mainly that 
involving electron transfer from the triplet pigment to the substrate 
(radical-involving). The singlet oxygen (102) - involving type was 
of minor importance. 
152 
Thus depending on the environment and substrate 
the two mechanisms may operate together or independent of each other, 
although there is growing evidence that the radical - involving pathway 
superceeds the 
102 
- involving pathway in tetrapyrroles dissolved in 
detergents, at pH 10. In some further attempts to simulate physiological 
conditions for phototherapy, certain investigators used erythrocytes 
which are known to bind significant amounts of bilirubin. 
153 
These cells 
35. 
used in vitro, would serve as models for testing the bilirubin possible 
phototoxic effects. Thus bilirubin caused the lysis of the haemoglobin-free 
erythrocyte ghosts as shown by the leakage of enzymes , with concomitant 
cross-linking of proteins. 
154 
The photooxidative enamine cleavage was also demonstrated with mesobilirubin 
from which was isolated methylethymaleimide. 
155 This circumvented the vinyl 
reactivity as mesobilirubin has ethyl, rather than vinyl groups. 
Obviously, what goes on during jaundice phototherapy is still a matter 
of speculation. In vivo studies are compounded by the fact that one or all 
processes, depending on the environment, may occur, Equations 2-4. 
Bilirubin 
hv450 
nm 
% Bilirubin* (1) 
Bilirubin-: 
- Energy 
Bilirubin (2) 
Bilirubin* 
HX 
Bilirubin. HX(adduct) (3) 
Bilirubin* 
02 
Oxidation products (4) 
Radiationless decay back to ground state, Equation (2). This probably leads 
to the currently observed geometrical isomers. 
Photoaddition, Equation (3). Photooxidation, Equation (4). 
(Asterisk indicates triplet excited state). 
In vivo bilirubin is largely associated with albumin. The albumin 
molecule contains unsaturated amino acid residues that react with singlet oxygen, 
and that in the presence of bilirubin, could compete with the pigment for 
singlet oxygen. 
156 Hence, the photooxidation of bilirubin in serum or in 
aqueous solutions containing albumin is likely to be slower than it would be in 
the absence of the protein. Under these conditions, the radical- involving 
process may assume greater importance. 
When aqueous solutions of bilirubin are exposed to air or oxygen in the 
36, 
dark, the pigment slowly disappears and is converted predominantly into 
colourless products. If the reaction is followed by spectrophotometry, 
a sequence of change is observed similar to the sequence observed when 
bilirubin is photooxidized. However, this reaction is completely inhibited 
by the presence of albumin, and so is the isomerisation into bilirubin 
III d and bilirubin XIII o. 
Aims of the Project 
Bilirubin is a powerful metabolic poison when used in a variety of in 
vitro systems, but the basis of pigment neurotoxicity in vivo is not 
understood. Therapy is directed towards preventing accumulation of 
bilirubin in excess of the infants' plasma binding capacity and toward 
rendering the pigment nontoxic and unable to penetrate the blood-brain 
barrier. 
It must be mentioned that the pigment does not have any well-defined 
physiological role, however, its association with jaundice has interested 
numerous biochemists, chemists and pharmacologists. Thus, bilirubin can 
be regarded as a probe for studying transport and biotransformation of 
many other non-polar compounds. It also enjoys a continued physiological 
interest because it is such an obvious solute in bile and shares the same 
or similar "carriers" for hepatic uptake and biliary transport with many 
other organic anions. 
The chemistry of bilirubin and its congeners has, therefore, aroused 
interests amongst organic, analytic, physico and photo-chemists and this 
may possibly lead to a clear understanding of the molecular biology of these 
pigments. 
The studies bear on two questions. How does bilirubin bind to serum 
albumin so as to facilitate its release for hepatic uptake? Secondly, where 
is the primary binding site of bilirubin on the albumin polypeptide chain? 
37. 
The binding site of a ligand on a macromolecule helps to understand the 
existence of excess ligand in plasma which may be due to competition 
with other ligands. 
The complete details of the photometabolism of bilirubin in the 
jaundiced bewborn and the mechanism of phototherapy, however, is still 
poorly understood. Specific aspects of the problem that merit further 
study include the following: The identity, toxicity, and mechanism of 
formation of the photoproducts require elucidation, and it needs to be 
determined whether the initially formed photoproducts are further 
metabolized to secondary compounds before they are excreted. Useful 
information regarding these points might be obtained from in vitro 
studies of the photochemical reactions of bilirubin bound to skin, 
lipid and albumin. 
38. 
Chapter 2 
2: 1 Introduction 
Clarification of several aspects of the metabolism of both 
endogenous and exogenous substances requires the preparation of these 
substances radiolabelled to high specific activity. Cases such as 
hepatic uptake of a number of substances can best be followed by 
introducing radiolabelled metabolites. 
For a long time a chemically stable, isotopically labelled 
preparation of bilirubin for biochemical and physiological studies of 
bilirubin metabolism, was desirable. Tritium gas was used for some 
time to label bilirubin in vitro, 
157 a, b but this method is both 
non-specific and expensive. Tritium is introduced all over the 
bilirubin molecule (Figure 1, structure 4). This method produced 
the products of low specific activity which were also very unstable 
physiologically or not suitable. 
Thus biosynthetic methods using the precursors of bilirubin 
were suggested using randomly labelled or -aminolevulinic-acid 
3H 
Q- ALA - 
3H) 
or cf - aminolevulinic acid - 3,5 - 
3H 
(0- ALA - 3,5 - 
3H) 
and c -aminolevulinic acid - 4C 
14.158-163 
(Figure 15, Structures 1,2,3, and 4 respectively). However, these 
early methods yielded products which were of relatively low specific 
activity, radiochemically unstable or physiologically unacceptable. 
Glycine -2- 
14 C an inefficiently incorporated biosynthetic precursor 
of the heure pigments was the first method to be employed to obtain 
14C 
- bilirubin. By improving the positions of tritium on the 
precursor ( of - aminolevulinic acid - 2,3 - 
3H, (- ALA)) 
(Figure 15, structure 2) resulted in labelled bilirubin with all tritium 
atoms in stable side chain positions and a specific activity many times 
39. 
greater than the previous products. 
164 
Obviously, most of these methods have their disadvantages as 
can '3e said of the low yields and low specific activities which are 
compounded with lack of stability of the radiobilirubin. Hence, it 
was open to investigators to think of new in vitro procedures of 
obtaining radiolabelled bilirubin. As is the case with research, a 
simple method free of limitations such as low intensity of labelling, 
cost of the precursor materials and laboriousness was reported. 
165 
(Figure 16). The tritium in the form of tritiated water in 
chloroform in the presence of thioacetic acid adds to the exo-vinyl 
group of bilirubin. The yield in this case was about 2% after pyrolysis 
of the adduct, with a specific radioactivity of 20, ACi/mmole. 
Recently, a new synthetic method of radiobilirubin was reported 
in our laboratory. 
166 
This method although it had a 40% yield 
was laborious since bilirubin dimethyl ester was the starting material. 
The tritium was introduced or incorporated into the methylene groups 
Ok - to the carboxyl groups 
in the propionic side chains. 
In an attempt to improve on the latter method, a one step 
procedure was developed for the preparation of (3H) - bilirubin IX -d 
in good yield from unlabelled bilirubin. This method is a development 
of a method introduced for the alkylation of aliphatic carboxylic acids. 
167 
2: 2 Materials 
n- Butyl-lithium, di-isopropylamine and hexamethylphosphoric 
triamide were obtained from Aldrich Chemical Co., Gillingham, Dorset. 
Bilirubin IX d was obtained from Sigma (London) Chemical Co., Kingston- 
upon Thames, Surrey, U. K. and was purified before use. 
168 
Tetrahydrofuran (AR. ) (THF) was distilled and dried over molecular 
sieves before use. Silia gel plates were obtained from E. Merck, 
40. 
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Experimental: 
To a solution of di-isopropylamine (0.2g, 2.0 mmol) in anhydrous 
tetrahydrofuran (80 mL) under a nitrogen atmosphere was added 
n- butyl-lithium in hexane (1.0 mL, 1.6 M) and the mixture was 
stirred at -78'C for 30 minutes. Bilirubin (58.4 mg, 0.1 mmol) was 
added and the mixture was stirred at -78'C for 30 minutes after which 
hexamethylphosphoric triamide (1.5 mL, 8.55 mmol) was added. The 
mixture was stirred for a further 30 minutes and then trifluoro (3H) 
acetic acid (0.546 mL., 4.8 mmol) was added which was prepared by treating 
trifluoroacetic anhydride with an equimolar amount of 
3 
H2O (5 Ci/mL; 
specific radioactivity approximately 100 nCi/mmol). The reaction was 
stirred for 4 hours at 21'C and then acidified with O. IM HC1 in an 
ice bath. 
The aqueous solution was extracted with chloroform three times 
(100 mL each), the chloroform extracts were combined, dried with sodium 
sulphate and evaporated to dryness in vacuo. The residual bilirubin 
was dissolved in chloroform (5m L) and purified by preparative t. l. c. on 
132 
silica gel with chloroform/methanol/water (40: 9: 1, by volume) as solvent. 
The yellow, band (RF 0.75) was excised and eluted from the silica with 
chloroform. The chloroform was removed in vacuo and the residual 
bilirubin was crystallised from chloroform/methanol (1: 1, v/v) to 
yield 19.5 mg. This bilirubin was then suspended in water and brought 
into solution by adding sufficient concentrated aqueous ammonia (specific 
gravity 0.88). After 5 minutes the solution was acidified with 1 MM - 
hydrochloric acid and extracted with chloroform (100 W. The 
chloroform was dried with sodium sulphate and evaporated in vacuo to 
give (3H) bilirubin. (19.3mg). 
42. 
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Table 2: 1 
Experiment 
33* 
59,650 
Specific radio activity 1.3uCi/mmol 
Literature 
166 
40 
60,000 
300uCi/mmol. 
* This overall yield was direct from unlabelled material unlike the 
indirect method through the dimethyl ester from the literature. 
n; ...,.....,. ,,.. 
The labelled bilirubin obtained was shown to be chromatographically 
pure146 and the non-covalently bound 
3H, 
possibly owing to the 
169-172 intramolecular hydrogen- bonding in bilirubin was removed by 
adding to an aqueous suspension of bilirubin sufficient ammonia to 
obtain solutions. Immediate acidification of the aqueous solution 
so obtained, followed by extraction with chloroform gave a quantitative 
recovery of bilirubin with a constant specific radioactivity. The 
reaction mechanism can be formulated as follows (Figure 17). Thus 
comparatively high yields are obtained provided that air, light and water 
are excluded from the reaction. In view of the known instability of 
bilirubin in alkaline 
173 
and in acidic solutions, 
146 it is possible 
that the bilirubin might isomerize under the conditions of the exchange or 
isolation. However, the only species that could be detected by thin 
layer chromatography was bilirubin - IX d. The diazotization of 
3H 
- labelled bilirubin gave azopigments with more than 99% of the 
specific radioactivity of the bilirubin. 
174 
This method for the 
one-step preparation of (3H) bilirubin from unlabelled material is 
preferable to the two - step procedure involving the preparation of the 
bilirubin dimethyl ester166 as the overall specific activity is higher 
45. 
and the radioactivity of the (3H) - bilirubin obtained is greater. 
By analogy with other reactions of metallated carboxylic acids, 
175 
it 
is assumed that only one 
3H 
atom was introduced into each 04 - methylene 
group of the bilirubin and no 
3H 
was introduced into the bridge methylene 
group as shown by diazotization. If placed in sealed vials and covered 
from light the (3H) bilirubin did not show any appreciable loss of 
radioactivity for many months. Such chemical methods for the labelling 
of are important because the isotope is placed at a point of interest. 
Unlike biosynthetic methods the fate of the isotope is known in less 
than a day. 
In the case of bilirubin biosynthetic methods are rather less 
specific because of the observation of the "early" and "late" labelled 
bilirubin. High yields of the labelled material can he used to try 
and avoid conventional methods for measuring small amounts of bilirubin 
in biological material, based on the diazo reaction, which have frequently 
proved unsatisfactory because of relative insensitivity at low pigment 
concentrations, problems encountered in standardization and loss of 
pigment through attachment to precipitated protein. Furthermore, 
labelling helps in overcoming the problem raised by tetrapyrrolic 
chromogens derived from bilirubin which cannot be estimated with p- 
dimethylamino benzaldehyde (Ehrlich reagent). 
These methodological shortcomings have hindered adequate study 
of several important aspects of bile pigment metabolism including: the 
mode of bilirubin transport in the serum at physiological concentrations, 
the mechanism of bilirubin exchange between serum and tissue proteins, 
the rate of conversion of bilirubin to non-bilirubinoid catabolites, 
and the nature and magnitude of the enterohepatic circulation of bile 
pigments. Thus isotopically labelled bilirubin of high specific activity 
46. 
will help elucidate some of these problems. 
Current controversies on the mechanism of phototherapy may also be 
clarified by following radiolabelled material. If for example photo- 
bilirubin is labelled in the propionic acid side chains, then it would 
be easy to follow whether its transport from the skin is carrier- 
mediated or not. Since several photoreactions have been reported on 
bilirubin, it will be interesting to observe whether labelled bilirubin 
injected in the Gunn rat will come in the bile in one form or another. 
This experiment can best be done with bilirubin labelled at specific points. 
Bilirubin labelled from either glycine or or- aminolevulinic acid would 
not solve the problem of the competitions between photoisomerisation 
and photo-oxidation during phototherapy. A cleavage at the very 
susceptible methylene bridge would result in a possible loss of the 
label on this central carbon. Whilst it is true that in vivo experiments 
may not have a 100 per cent recovery, our labelling method i. e. tritium 
on propionic acid side chains would be used to answer questions such as: 
which is formed first, methylvinylmaleimide or hematic acid? 
Elemental analysis is also necessary in biosynthetic methods least 
a different chromogen of similar properties has been formed. It is also 
known that the only way to increase the yields of biosynthetic methods 
is by using 'a bigger animal or increase the amount of the isotope. 
For technical and economic reasons this would be rather disadventageous. 
47. 
Chapter 3 
3.1 Introduction: 
In the plasma, bilirubin is reversibly bound to serum albumin and 
is transported to the liver where it is conjugated and then excreted. 
Although, many experiments have been done to locate the exact domain of 
albumin which binds bilirubin, no conclusions have yet been made as to 
the exact site of the binding. For example, affinity labelling of human 
albumin with bilirubin that had been activated with Woodward's reagent 
K (2 - ethyl-5m - sulphophenylisoxazolium hydroxide) 
123,176 
indicates that 
two regions (residues 124 - 297 and residues 446 -547) are attached to 
the bilirubin. Similar experiments were done to attach bilirubin to its 
high-affinity site using ethyl-3(3-dimethylaminopropyl) carbodiimide 
hydrochloride. 
177 
However, objections can be raised to the activation 
of bilirubin by the above reagents as they would interact initially with the 
carboxy groups of the bilirubin and for covalent attachment a suitably 
nucleophilic amino acid side chain of the albumin must be present in a 
favourable position in the binding site. Thus purely hydrophobic 
interactions between the albumin and the bilirubin are unlikely to be 
revealed by these methods. 
The binding of bilirubin to the high-affinity has also been studied 
using chemically modified albumins. 
122'123 
It can be concluded that at 
least one reactive amino group is located at the bilirubin binding site as 
trinitrophenylation of its group inhibited the bilirubin binding. Later 
experiments, however, revealed that a lysine - 240 of the human albumin 
is involved in the high-affinity binding site of bilirubin, 
124 
and also 
that the modification of the histidine, arginine and tyrosine residues 
decreased the binding affinity, whereas modification of a limited number 
of amino (dansylation)178 and carboxy groups, the single cysteine and 
single tryptophan residues does not change the affinity for bilirubin. 
122 
48. 
Coupling of ligands (dyes) to albumin by sensitized photooxidation 
has previously been done to help in the study of the geography of the 
binding sites. The dye (4 - azidobenzoyl-pentagastrin) was coupled to 
bovine serum albumin by sensitized photooxidation. 
179 
Thus, although 
bilirubin is a poor sensitizer, there is a possibility of coupling it 
to human albumin. The imidazole rings of human serum albumin are 
destroyed by photooxidation in the absence of a ligand resulting in a 
decreased capacity for protein binding of bilirubin. 
180 
However, 
irradiation of albumin with ultraviolet light does not change the 
affinity of the protein for bilirubin. 
181 
Phototherapy has been 
employed in a prophylactic manner to modify the degree of hyperbilirubinemia 
in premature infants and also to reduce bilirubin concentrations in older 
infants with congenital non obstructive, non-hemolytic jaundice. Despite 
widespread usage of phototherapy in newborn nurseries, the mechanism by 
which the serum bilirubin concentration is lowered is not yet known. 
In vitro studies have shown that bilirubin undergoes decomposition 
when exposed to light of varying sources 
182-184 
and so does in vivo 
studies. 
185 
It should be mentioned that in vivo bilirubin is strongly 
bound to albumin, furthermore, a visible decrease in skin coloration is 
observed instead of the increase expected as a result of the release of 
albumin bound bilirubin. Thus further investigations would be necessary 
to explain this disappearance. The nature and cytotoxicity of the 
possible photoproducts of bilirubin has warranted the study of the effect 
of light on bilirubin in the presence or absence of serum albumin. 
Experimental 
3: 2 Effect of Light on bilirubin IX -(: Y, 
Photodecay of bilirubin in organic solvents has been done by many 
investigators. In an attempt to simulate physiological conditions, the 
49. 
Fig. 18. Photodecay of bilirubin in the absence 
of human serum albumin. 
Fig. 19. Photodecay of bilirubin in the presence 
of human serum albumin, 
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photodecay was followed in the absence and presence of human serum 
albumin (1iSA). 
3: 2: 1. Photodecay in the absence of HSA 
A solution of bilirubin (5.13 x 10-5 M) was made by dissolving 3mg 
in 0.1M sodium hydroxide (0.20 mL) and 1mM ethylenediaminetretraaceti 
acid (EDTA) (0.10 mL) and diluted to 100 mL with 0.10M sodium phosphate 
buffer, pH 7.4. Some of this solution (4.0 mL) was added to a cuvette 
and read on a spectrophotometer to determine the maximum wavelength. 
With a maximum wavelength at 436 nm, this bilirubin solution in 
the cuvette was exposed to light from a lamp of 1000 W and the absorbance 
was read every 15 minutes for a total period of 135 minutes. Figure 18, 
shows the rate of decay of bilirubin in the absence of HSA. 
3: 2: 2 Photodecay in the presence of HSA 
A solution of charcoal-treated HSA (5.13 x 10-5M) was made by 
dissolving 34.0 mg in 0.10M sodium phosphate buffer, pH 7.4 (100 mL). 
The bilirubin solution (5. OmL) was added to an equal volume of the HSA 
solution. This mixture (4. OmL) was added to a cuvette and the maximum 
wavelength determined as before. 
The decrease in absorbance at 460 nm () max) was followed every 15 
minutes for a total period of 150 minutes as shown in Figure 19. 
Photodecay of a fresh solution of the bilirubin - albumin complex 
was done using a filter which absorbs at 325 - 400 nm and 520 - 700 nm. 
The decrease in absorbance at 460nm was followed for 150 minutes (Figure 20). 
And Figure 21 shows the rate of decay in the absence of HSA using the 
filter mentioned above. 
The rate of decay was also followed at respective maximum wavelengths 
of bilirubin - albumin complex and bilirubin using a blue filter 
50. 
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(Figure 20 and 21 respectively). 
3: 2: 3 Succinylation of human serum albumin. 
When bilirubin binds to HSA, a strong bathochromic shift is 
observed at physiological pH (7.4). Thus in O. lM sodium phosphate 
buffer pH 7.4, bilirubin has a maximum absorption at 436 nm which 
shifts to 460 - 462nm on binding to albumin. 
Albumin was succinylated by dissolving 3.0 g in distilled water 
(50 mL) to which succinic anhydride (0.940 g) was added in several 
portions at room temperature. The pH was kept at 8.0 by adding 3.5M 
potassium hydroxide. After each addition, an aliquot was removed from 
the reaction mixture for absorption measurement in the range 350 - 250 nm 
(Figure 22). The reaction was allowed to proceed for one hour and kept 
at room termperature for 30 minutes. The mixture was then dialysed 
extensively against water for 36 hours at 4°C after which it was 
lyophilized. 
186 
Succinylation is followed by the disappearance of absorption at 
278 nm of the albumin (Figure 22). Succinic anhydride reacts with 
e-lysine, histidine, cysteine, serine, threonine and tyrosine. Thus 
the loss in absorbance at 278 nm is due to the reversible reaction with 
tyrosine residues of the albumin. 
To succinylated - HSA (Succ - HSA) (5.0 x 10-5M) in 0.1M sodium 
phosphate buffer, pH 7.4 (5. OmL) was added bilirubin (4.5 x 10-SM) and 
1.0 x 10-4M), (5. OmL) in each case. The spectrum of each mixture 
(4. OmL) was taken on an SP 800 UV spectrophotometer immediately after 
mixing as shown in Figure 23. 
3: 3. Photo-affinity labelling of Human Serum Albumin with (3H) - Bilirubin. 
Photooxidation of proteins in the presence of sensitizers, such as 
51. 
rose bengal or methylene blue, generally involves a singlet - oxygen 
attack on histidine residue. 
187 
Also the naturally occurring pigment, 
bilirubin, is able to transfer excitation energy to molecular oxygen. 
188,189 
Extensive use of phototherapy in newborn infants with hyperbilirubinemia 
has stimulated research in this field and the question has been raised 
whether bilitubin is photooxidized in the skin during phototherapy, 
and whether it also sensitizes photooxidation of the serum albumin to 
which it is bound in the blood plasma. 
180,190 
Reports in literature vary 
greatly as to the "correct" time the bilirubin should be irradiated 
as a result the photoproducts thus reported reveal similar variations. 
However, the pholvproducts do not increase after 24 hours of irradiation 
(pH 7.8) neither do they have any inhibitory effect on mitochondrial 
respiration especially with succinate as the substrate. Photodegradation 
products may also bind to albumin, in which case the effect on 
mitochondrial function would be diminished. 
190 
Thus to alleviate the 
possibilities of the cytotoxicity of the photoproducts the time of 
irradiation is of importance. 
These in vitro experiments do not reflect completely in vivo 
studies since it is believed that the effect of phototherapy in the Gunn 
rat is to enhance the output of either bilirubin or bilirubin anion. 
Therefore, the major pathway of phototherapy may not involve 
photooxidation or photodegradation of bilirubin; instead, it may 
involve enhanced excretion of bilirubin IX 0.. 
191 This finding is 
supported by studies of the effect of phototherapy on jaundiced babies. 
192 
Recent developments in this area have proposed the formation of 
metastable geometric isomers that are transported in blood and excreted 
in bile. This two views appear on this field of the mechanism of 
phototherapy. One interpretation postulates the self sensitized 
52. 
photooxidation of bilirubin 
193 in the skin 
194-197 An alternative 
view involves the ZZ ZE and EZ photoisomerisation of the meso 
bridges 198-202 to form more soluble products. 
14C labelling experiments203 
have yielded results capable of lending support to either mechanism in 
that unchanged bilirubin appears in the bile and lower molecular weight 
(presumably photooxidation) products appear in both bile and urine. 
Although the structure of the product has not yet been elucidated, 
the spectrum and differential absorption spectra has been reported. 
199-201 
These parameters suggest that the product is a photoisomer (EZ, ZE or a 
mixture). Laser flash photolysis studies identified a transient. decaying 
and a permanent product in the presence of human serum albumin, the former 
having a time for half reaction of about 3,, ýus. 
204 
The transient 
is believed to be an excited state which internally rotates on decay to give 
a photoisomer. However, the lifetime of the transient (3 /u s) is for 
too long lived for a singlet excited state but shorter lived than the 
triplet. 
133 
If the transient is a triplet, its shorter lifetime in 
HSA may be due to a quenching reaction with histidine or tryptophan 
residues in the protein. This explanation would be consistent with the 
observed destruction of these residues following irradiation of bilirubin- 
human serum albumin mixtures. 
205 However, explanation cannot be found as 
to why this species is insensitive to the presence of oxygen or iodide 
ion; possibly the bilirubin is protected by the protein. 
All this does not give or explain the mode of formation of the 
transient and product. A possible scheme as suggested204 may be the 
following: 
BR (So) 
by BR (S1) uni--l BR-* -uni-----'i BR (So) 
(ZZ) (ZE and EZ) 
where BR* may be a triplet state. 
53. 
Since bilirubin may well be internally hydrogen bonded in the 
hydrophobic cleft of the protein, the activation energy could be 
made from the contributions of 38 kJ 
172 for the rupture of three 
hydrogen bonds plus about 10-20 k7 for an excited state rotation of 
a pyrrole unit about the meso bridge. 
206 
Although on steric grounds 
aZ to E photoisomerisation is quite acceptable, the photoproducts 
should not exhibit any 7- delocalisation over the bridging single 
bonds adjacent to the isomerised double bond. 
207 
As bilirubin 
contains two oxodipyrromethene moieties, three photoproducts of this 
type are possible, viz. Z-E, E-Z, E-E. If the colour of bilirubin 
is dependent on the J7 - delocalisation then the last of these 
photoproducts should have very different spectral properties from the 
others. 
3: 3: 1 Time-course for the covalent binding of (3H) - bilirubin to HSA. 
A solution of (3H) - bilirubin (65uM) was prepared by dissolving 
3.8 mg (sp. radioactivity 1.3 x 109 cpm/mmol. ) in 0.10M - Na OH 
(0.2 mL) anI diluting to 100 mL with 0.10M - sodium phosphate buffer, 
pH 7.4. A mixture of this solution (5. OmL) and a solution of human 
serum albumin (SmL, 65uM) in 0.10M - sodium phosphate buffer, pH 7.4 
making a total of eight aliquots, were irradiated for 15,30,45,60, 
75,90 and 120 minutes, at 40 cm from a tungsten lamp (150W). A 
similar control was placed in the dark. 
Each reaction mixture was then applied to a column (0.90 cam x 
54. 
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15.0 cm) of Sepharose-albumin in 0.05M sodium acetate, pH 4.5.126 The 
column eluate was dialysed against 2 litres of 12.5 mM - sodium salicylate, 
pH 7.4, for 48 hours and then against 2 litres of 0.10M - HC1 for 24 hours 
after which time a non-diffusible bilirubin-albumin complex was obtained. 
3: 4. Degradation of the Bilirubin/Albumin Complex. 
The structural features which give albumin its unique binding 
properties as a transport protein are not yet fully understood. To 
anticipate binding interactions and better to understand albumin function, 
a greater knowledge of binding mechanisms and the localization and 
specificity of ligand binding sites on albumin is required. Major 
advances in our understanding of these areas have occurred in the last 
few years since the elucidation of the primary sequence and structure of 
albumin. One consequence of the structure of albumin is that fragments 
produced by limited proteolysis retain, to a large extent, their 
original structual and binding oroDerties. Through studies of the 
binding of ligands to such fragments, specific binding sites have now 
been located on the albumin molecule. 
The strongest fatty acid sites appear to be located within the 
carboxy-terminal two-thirds of the molecule, the first site lying within 
the amino acid residues 377-503. A second less definite site lies 
between loops-5 and 6.208 These sites appear to display considerable 
structural specificity and are not available for the binding of other 
organic ligands. However fatty acids binding can affect the binding 
sites of other ligands on albumin as a result of the conformational change 
in the albumin molecule which they may induce on binding. 
209 
Studies 
of bilirubin binding to proteolytic fragments, 
208,210-212 
together with 
55. 
affinity have established that the ty labelling studies, primary 
bilirubin binding site is in the region of loop 4. Certain proteolytic 
fragments of the human albumin molecule (residues 1 -386 and residues 
49-307) were shown to bind bilirubin. L-tryptophan has been shown to 
be bound by fragments (residues 1-136) and (124-298), 
215 
with affinity 
studies locating the site near histidine 146, which occurs at the top 
of loop 3. Thus a common cavity or close binding sites of bilirubin 
and L-tryptophan do exist in the region of residues 124-298, and is 
sufficient enough to contain both ligands. 
It has been demonstrated previously that neither lysine - 199216 
nor tryptophan - 214122 is involved in the bilirubin 
binding, as modification of these residues had no influence on the 
binding affinity. It should also be mentioned that dansylatiun of more 
than one lysine affects the binding of bilirubin. There is also 
experimental evidence that the location of the bilirubin binding site 
is 28A0 from the fatty acid primary binding site. 
3: 4: 1 Experimental: 
This was done according to McMenamy et al. 
217 
A solution of labelled human serum albumin was made by dissolving 
100 mg in distilled water (l. OmL) and formic acid (4. OmL). To this 
mixture was added cyanogen bromide (100 mg). 
The solution was allowed to react for 24 hours at 4°C . The 
solution was then diluted with distilled water (1: 1 by vol. ) and 
chromatographed on a column (2.5 x 40 cm) of Sephadex G- 25 (coarse) 
in l% propionic acid. The protein was collected and concentrated to 
5.0 mL in a Diaflo apparatus PM 10 membrane ultrafilter, Amicon 
Corporation at a pressure of 15 p. s. i. 
The concentrated solution was fractionated on a Sephadex G- 100 
56. 
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column (2.0 x 90 cm) with 5% propionic acid, 0.1M NaCl at 22'C. The 
flow rate was 30 mL to 50 mL per hour (Figure 25). The radioactivity 
was determined in the fractions of the eluate and was found associated 
with zone II (Figure 25). Fractions from ZONE II were pooled, 
diluted 1: 1 with distilled water concentrated as before to about 
5. OmL. The pH was raised to 3.3 and then placed on a carboxymethyl- 
cellulose column (3.5 x 5.0 cm) (Whatman CM-32). The elution was done 
with 0.05 to 0.3M NaCl gradient in 0.01M P04, pH 2.7 at 22'C with a 
flow rate of 400 to 600 mL per hour (Figure 26). 
The fractions, pooled from peaks D and F (Figure 26) were adjusted 
to pH 4 to 4.5 by addition of 1M NaOH and concentrated as stated above. 
Radioactivity was determined by adding aliquots (100 uL) of each peak 
to a scintillant Toluene/ethoxyethanol/PPO/POPOP. Protein concentration 
was determined by the method of Lowry et a1218 and the material was 
subsequently lyophilized. 
3: 4: 2. N-terminal analysis: 
The N-terminal amino acid for the peptides were determined 
following the procedure of Gray. 
219 
After oxidation with performic 
acid, the peptide (0.3mg) was dissolved in 50uL 1% SDS in a small pyrex 
test tube and 50 uL N-ethylmorpholine was added. A freshly made 
solution ofdansyl chloride (25 mg/mL, 75 uL) in anhydrous dimethyl 
formamide was added and mixed; the reaction was allowed to proceed 
at room temperature for 3 hours after which the labelled peptide was 
precipitated by adding acetone (0.6mL) to the reaction mixture. The 
resulting precipitate was compressed by centrifugation, washed with 
80% acetone (500 uL) centrifuged again, dried by evaporation in vacuo 
and hydrolysed with 6N HC1 
(150 uL) at 110'C for 18 hours. The 
resulting dansyl amino acid was identified chromatographically by 
57. 
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comparison with dansyl amino acid markers on polyamide layer sheets 
employing the solvent systems of Hartley. 
220 
The dansylated amino acid 
was visualised under ultraviolet light and the position of the spot 
corresponding to the dansyl aspartate and cysteine markers coincided 
with that of the spots arising from the hydrolytic products of the 
dansylated peptides. Aspartic acid and cysteine were therefore judged 
to be the N- terminal amino acids of peptides D and F respectively. 
3: 4: 3. Treatment of peptide F. with pepsin. 
The method employed was according to Franglen and S waniker. 
221 
The peptide (10 mg) was dissolved 1.5 mL of distilled water 
and the pH was adjusted to 2.45 with 1M - HC1. To this was added 
pepsin (0.033% w/v in 1mM - sodium acetate buffer, pH 5.40,20 uL) for 
10 minutes at 25 + 0.1'C. The reaction was stopped by 1M - K2 HP04 
until the pH was raised to 8.0. The hydrolysate was further subjected 
on a column (0.6 x 60 cm) of Sephadex G- 10 in 50 mM - sodium phosphate 
buffer, off 7.70 containing 0.15M Na Cl. Fractions were collected 
2.0 to 3.. 0 mL and the extinction coefficients at 220 run and 280 nm. react. 
The peak associated with over 85% of the radioactivity (Figure 
27) was pooled and lyophilized. A portion of it was further purified 
on column and the paper chromatography (descending) using n- butanol/ 
acetic acid/water, (5: 2: 3, v/v) as the solvent system. Spraying with 
5% ninhydrin in n-butanol showed a single spot. The whole peptide 
was dialysed against 0.1M NaCl for a day and distilled water for 24 
hours and subsequently lyophilized. 
3: 4: 4 Amino Acid Analysis 
from pepsin-treated 
The amino acid analysis was done on a purified peptide/F on 
a Locarte automatic acid analyser. Table 3.1 shows the amino acids 
found in the labelled peptide. Residues are expressed as mmoles 
58. 
per mg of peptide. 
Table 3: 1 
Asp 1.8 Val 1.2 
Thr 0.9 Met 0 
Ser 1.8 Ileu 0.6 
Glu 2.7 Leu 1.1 
Pro 2.0 Tyr 0 
Gly 4.4 Phe 0.7 
Ala 5.0 His 0.5 
Cystine 0 Lys 0.9 
Arg 0.5 
Table 3: 2 Residues 216-264 
Asp (5.0) 
Thr (3.0) 
Ser (2.0) 
Glu (5.0)" 
Pro (1.0) 
Gly (1.0) 
Ala (6.0) 
Cystine 0 
Val (4.0) 
Met 0 
I leu (1.0) 
Leu (6.0) 
Tyr (1.0) 
Phe (2.0) 
His (2.0) 
Lys (4.0) 
Arg (3.0) 
46.0 
Cysteine 3.0 
59. 
The amino acid content was determined by Dr. J. E. Fox, Macromolecular 
Analysis Service, Birmingham University. 
3: 4: 5. Location of the peptide in the albumin sequence. 
Human albumin is provided with two unique amino acid markers, 
the single tryptophan residue at position 214 and the free thiol group at 
position 34 in the sequence. 
Table 3.2: 
Fragment F. Residues 
215-241 216-242 
M B M B 
Asp 1.8 (3.6) 1.0 1.0 1.0 1.0 
Thr 0.9 (1.8) 2.0 2.0 3.0 3.0 
Ser 1.8 (3.6) 2.0 2.0 2.0 2.0 
Glu 2.7 (5.5) 3.0 3.0 3.0 3.0 
Pro 2.0 (4.0) 1.0 1.0 1.0 1.0 
Gly 4.4 (8.8) 0.0 0 0 0 
Ala 5.0 (10.0) 4.0 3.0 3.0 3.0 
Cystine 0 (0) 0.0 0 0 0 
Val 1.2 (2.4) 4.0 4.0 4.0 3.0 
Met 0 (0) 0.0 0 0 0 
Ileu 0.6 (1.2) 0.0 0 0 0 
Leu 1.1 (2.2) 3.0 3.0 3.0 3.0 
Tyr 0 (0) 0 0 0 0 
Phe 0.7 (1.4) 2.0 2.0 2.0 2.0 
His 0.5 (1.0) 0.0 0 1.0 1.0 
Lys 0.9 (1.8) 3.0 3.0 3.0 3.0 
Arg 0.5 (1.0) 2.0 2.0 2.0 2.0 
Total 24.1 (48.5) 27.0 26 27.0 27 
Residues 
60. 
NH2 - terminal, Val 
One of the residues is Gin. 
Table 3: 2 shows the composition of the peptic fragment with the highest 
amount of radioactivity. The peptide was judged to have valine as the 
N- terminal residue. For comparison, the nearest compositions of 
Behrens et al (1975) (B)88 and Meloun et al (1975? (M) are shown. There 
is likely to be a high level of contamination due to Glycine. 
ni cnncei nn 
Effect of Light on bilirubin IX-d, in the presence and absence of 
human serum albumin. 
All experiments were done in darkness and the only source of 
light was the lamp. Light from the lamp decomposed bilirubin in the 
presence and absence of the albumin but relatively slower in the former. 
This protective nature of albumin at molar ratios less than unity shows 
that the pigment is completely bound to the high-affinity site. This 
photobleaching of bilirubin in vitro agrees with the studies observed in 
the Gunn rata. 
222 
The screening of light through particular filters did not change the 
rate of photodecay with the exception of theblue filter which almost 
inhibits the process. This photodecay of bilirubin is probably oxidative, 
although exclusion of oxygen does not arrest photodecay in the presence 
or absence of albumin. Presumably, albumin itself or the vinyl side 
chain of bilirubin substitutes for oxygen as a hydrogen acceptor. 
222 
The stability of bilirubin to photodecay in the presence of HSA increases 
with increasing pH and less so at lower pH values. 
222 This could 
be attributed to the binding of the bilirubin dianion at higher pH values. 
Biliverdin is speculated to be an early intermediate in the photo- 
decay of bilirubin and that it is stabilized in neutral albumin solution 
(pH 7.4). The proportion of photoderivatives of bilirubin in the 
61. 
absence and presence of albumin is pH independent but in the latter case 
slowly migrating spots are observed in large quantities. 
222 
Although 
the photolysed solutions were not chromatographed in these experiments, 
products with the maximum wavelength towards the shorter wavelength to 
that of bilirubin were observed. Bilirubin is, therefore, stable under 
red light and in protein solutions; but EDTA alone even to the exclusion 
of oxygen does not protect the pigment. 
Effect of succinylating human serum albumin: 
Succinylated - HSA was shown spectrophotometrically not to bind 
bilirubin at molar ratios of 1.0: 0.9 and 1.0: 2.0 respectively (Figure 23). 
Succinic anhydride reacts with a number of albumin residues which have 
previously been shown to be in the vicinity of the binding site of bilirubin. 
Although the reaction is reversible with tyrosine, the modified albumin 
does not have an observable change in its binding affinity for bilirubin. 
Furthermore irradiation of succ - HSA/ bilirubin complex in 0.10M sodium 
phosphate buffer pH 7.4, does not arrest the decay of the pigment. 
This further confirms that lysine and histidine in particular are 
important in the binding of bilirubin to albumin, since the modified 
albumin has less or no affinity for the pigment. 
The Effect of time of irradiation of albumin bilirubin complex: 
In a typical experiment, after irradation for 60 minutes a solution 
of albumin (5. Omg/mL) had an absorption of 0.50 at 450 nm after 
chromatography on Sepharose - albumin column. When the experiment was 
repeated with degassed solutions and with N2 flushing during the irradiation, 
the residual specific radioactivity was the same (Figure 24). If the 
irradiation step was omitted the specific radioactivity of the albumin - 
bilirubin complex was 2.0 x 106 cpm/mmol of albumin. The non-diffusible 
albumin-bilirubin complex of the highest specific radioactivity 
(5 x 107 
62. 
cpm/mmol of albumin) was obtained after 60 minutes, of irradiation. 
However, photoinduced binding was observed to occur even after 15 minutes 
of irradiation. 
The break after 60 minutes (Figure 24) may be attributed to the 
decrease in the content of histidyl, tyrosyl and tryptophyl residues, 
hence the probably unfolding of the albumin molecule. It is likely 
that the integrity of at least some of these amino acid side chains is 
critical for maintaining the native three dimensional geometry of the 
albumin molecule; consequently molecular regions not closely adjacent 
to the bilirubin binding site became accessible to the photoreactive 
species. It has been shown that there is an initially preferential 
modification of 1.5 -2 histidyl side chains in HSA which is connected 
with the well-documented spatial selectivity of dye-sensitized photoreactions223 
so that only those amino acid residues which are adjacent to the dye 
undergo photooxidation in the early stages. 
Photobilirubin, which has been shown to be a geometrical isomer 
of bilirubin, 
202,224 is the unstable intermediate present in the serum 
from irradiated rats, and it also binds to serum albumin. Depending on 
the time of irradiation a mixture of ZZ 7 EZ = ZE > EE geometrical isomers 
of bilirubin will exist in solution, and the isolation and purification 
of the intermediate is made difficult by its thermal reconversion to 
bilirubin (ZZ). This agrees with the observations (Figure 24) that flushing 
with N2 did not have an appreciable effect on the bound pigment. 
The relative concentrations of albumin and bilirubin were chosen so 
the 
that/high-affinity binding site in the albumin was just fully occupied. 
Thus it was hoped that complications due to the binding of bilirubin at 
high - and low - affinity sites do not arise to a significant extent. 
It was difficult to remove final traces of radioactive bilirubin from 
the albumin even when no irradiation takes place. A combination of 
63. 
chromatography on an affinity column against sodium salicylate and 
O. lM - HC1 failed to remove the final traces of radioactivity. However, 
the covalent attachment of bilirubin to the albumin after irradiation could 
be clearly demonstrated by degradation of the albumin - bilirubin complex 
with cyanogen bromide (CNBr). 
217 
No radioactivity was associated with 
the degradation products unless irradiation of the complex had taken 
place. 
Pre-irradiated albumin does appear to bind bilirubin less 
strongly; an observation shared by other investigators. 
181,206 
Photo-oxidation of proteins in the presence of photosensitizers is well 
known; 
225 
however, there is some controversy on the capacity of bilirubin 
to induce the photo-oxidation of serum albumin to which it is bound. 
Experiments in D20, in which singlet oxygen (102) has a longer half- 
life than in H2O produced more or less similar results with specific 
radioactivities of 1.92 x 106 cpm/mmol of albumin and 2.0 x 107 cpm/mmol 
of albumin for non-irradiated and irradiated complexes (60 minutes) 
respectively. However, it has been generally assumed that the 
occurrence of protein photomodification is unlikely, owing to the high 
reactivity of bilirubin for 
102 
coupled with the relatively low 
efficiency of 
102 
generation by electronically excited bilirubins. 
130,189,191 
This assumption is in contrast with the photodamage of various biomolecules 
induced by bilirubin. 226,227 Some photoproducts of bilirubin e. g. 
methyvinylmaleimide photogenerate both 
102 
and radical species, 
228 
which may thus often display absorption spectra overlapping with that 
of typical bilirubin. Moreover reaction mechanisnsinvolving transient 
species other than 
102 (e. g. radical itermediates) have been shown to be 
involved in the bilirubin photochemistry to an extent depending on 
bilirubin conformation and solvent polarity. 
171,229 
lt has also been 
pointed out that albumin-bound bilirubin undergoes photodegradation 
64. 
even in the oxygen-free solutions. 
205 
It should be mentioned that 
the formation of dye-protein ground state complexes prior to irradiation 
strongly favours the occurrence of type I (radical involving) process 
in photosensitized reactions. 
223,230 
There is, however, growing 
evidence that anaerobic photoisomerization is the major mechanism 
for increased bilirubin turnover during phototherapy, rather than 
photo-oxidation. 
224 
Degradation and amino acid analysis of the labelled pigment: 
In the quest to find the mechanism of phototherapy and hence 
the excretion of unconjugated bilirubin and thepossible 'cytotoxic' 
photoproducts, two major hypotheses have been put forward. The first 
of which is that oxygen is involved in photodegradation of bilirubin. 
Although a number of products such as methylvinylmaleimide have been 
found in in vitro studies, the protective nature of HSA in vivo does 
pose a question as to the feasibility of this method in phototherapy. 
It should not be ruled out though that bilirubin photodecomposes 
rather slowly in the presence of albumin, and even in oxygen-free 
solutions. 
205 
The amino acid analysis Table 3: 1 shows a decrease 
in the amount of amino acid residues which have previously been shown 
to exist in or around the bilirubin binding site. The irradiation 
experiments are time-dependent (Figure 24), as is shown by the break 
after 60 minutes, which explains a possible chemical and conformational 
change of the HSA. In addition to these is the decrease in the binding 
affinity for bilirubin by albumin. On the other hand some investigators 
231 
did not find any change with HSA after 60 minutes irradiations of its 
bilirubin complex with eight 20W/15 Ostram fluorescence lamps. This 
observation has been attributed to the total light intensity used. 
205 
It is believed that there is a preferential modification of 1.5 - 2.0 
65. 
histidyl side chains, 
223 
the importance of which has been inferred 
from the data of chemical122 and photosensitized180 modification studies. 
It is also possible that the bilirubin photoproducts may possess 
photosensitizing properties for amino acids, hence can promote further 
modifications even when bilirubin has been degraded; since several 
of them are water-soluble. 
139 The second, and a rather current 
favourite, is that bilirubin IXc. has aZ configuration at the meso 
bridge double bonds, which undergo rapid and reversible photo- 
isomerisation on irradiation with visible light giving Z-E, E-Z and 
E-E isomers. The non - Z-Z isomers of bilirubin - IX 01 are less 
lipophilic and more polar than the natural Z-Z isomer. However, this 
process is further clouded by the fact bilirubin - IX of photoisomerizes 
anaerobically in aqueous solutions simulating the natural environment, 
to a mixture of III, IX and XIII o( isomers. The III and XIII oC 
isomers also give the Z-E, E-Z and E-E isomers. 
200 
These observations, 
although not made in these studies do reflect a possible mechanism 
of phototherapy, since in vivo studies have shown that the properties 
of the photobilirubin(s) are similar to those of the Z-E, E-Z and E-E 
isomers. 139,202,224 It is also noteworthy that bilirubin is a 
dianion in the binding cleft, 
129 
hence little energy is required to 
break the remaining hydrogen bonds. There also exists a rather subtle 
process that is the photoaddition of bilirubin139 which in itself 
would not probably help the mechanism of phototherapy and thus 
contradicts the observed increased turnover of bilirubi. n after 
phototherapy. Irradiated bilirubin undergoes regio-specific addition 
at the exo-vinyl group. 
232 It is therefore possible that 
to 
photoaddition/bilirubin by some amino acid of HSA does occur. In 
these studies a non-diffusible bilirubin attached to HSA was observed, 
233 
which is supported by the photo-induced binding observed by Rubaltelli 
and Jori(1979). 
205 
The nucleophilicity of sulphydryl and alcoholic 
66. 
functions, the former being more nucleophilic would probably have cysteine, 
methionine, threonine and Serine as the possible candidates. Table 3: 1 
shows the amino acid composition of the peptic fragment of the albumin 
region (residues 124-297) which was associated with radioactivity. 
It is therefore tempting to propose a photoaddition on to the exo-vinyl 
of bilirubin by the residues threonine or serine depending on the spatial 
selectivity for the following reasons: 
a) photochemical addition of alcohols and thiol containing groups 
has been observed; 
139 
b) the endo-vinyl group is less reactive than the exo-vinyl 
group, thus the formation of the E-Z configurational isomer will be 
permitted around the 5- meso double bonds. This is further supported 
by the evidence that the E-Z isomer is more mobile that the Z-E isomer; 
and thus reverts to the Z-Z configuration faster than the Z-E isomer. 
200 
Besides photobilirubin (a mixture of E-Z and Z-E isomers) binds to 
serum albumin; 
202 
a) during phototherapy, substances derived from bilirubin (but 
not identical or isomeric with it) are excreted in bile and urine. 
Although the nature of these is obscure, it is possible that they could 
be dipyrrolic propentdyopent - like compounds that are excreted, during 
185,234 
treatment, in-urine; 
d) any feature that disrupts the usual hydrogen-bonded system 
and makes the tetrapyrrole more soluble in water, is sufficient to make 
it readily excretable. 
231 Thus structural features of bilirubin namely 
an sp3 carbon at C- 10 and two propionic acid side chains at C-8 and 
C- 12 give the pigment poor excretability compared to biliverdin - IXd "235 
At least part of the serum bilirubin in animals and humans exposed to 
natural and artifical light is eliminated as photoadducts with nucleophilic 
substances, for instance GSH and, by implication, albumin* 
142 
Obviously, 
albumin is appropriate to give an irreversible adduct with bilirubin; 
67. 
in fact, it is well recognized that a reversible albumin-bilirubin 
complex107,236a, 
b 
occurs in the extracellular fluids of the body. 
This does not in any way contradict the previous observations, 
but rather adds to the fact that several reactions are likely to occur 
during phototherapy, with the preponderance of photoisomerisation 
(Z --: ýE configurational change), photo-oxidation and photoaddition. 
Until the nature of the photoproducts is clarified, the above processes 
all seem to point out towards production of more polar derivatives which 
are easily excreted compared to the natural pigment bilirubin - IX of 
So far the following mechanisms have been proposed for phototherapy: 
(Figure 28). 
Figure 28. 
a) Photoisomerisation: 
202 
. w, BR F- BR - albumin - BR 
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skin Blood Liver Bile 
185,234 b) Photo-oxidation: 
Light - BR-i-% BR-Albumin? 
II 
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c) Proposed mechanism based on photoadditions 
PBR - albumin I 
Light --ý BR - BR - albumin BR photoadduct 
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skin Blood Liver 
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Bile 
The bilirubin-photoadduct has to be more polar than bilirubin to facilitate 
68. 
its excretion. 
Figure 28: Mechanisms of bilirubin excretion during phototherapy of neonatal 
jaundice. (BR, 4Z, 15Z - bilirubin IX o< ; PBR, photobilirubin; and 
oxidation products e. g. dipyrrolic propentdyopent - 
like compounds). X, 
any compound (e. g. GSH) which can be added to the bilirubin. It is important 
to note that photoproducts of bilirubin 
in the presence of HSA are different 
from those in the presence of BSA; the latter being identical to the CHC13 
ones. 
Location of the peptide in the albumin sequence 
The N- terminal of the peptide was judged to be valine. No other 
sequence work was done so the tentative location was on the following reasons: 
a) Lysine - 240 has been shown to be on the bilirubin binding site. 
The amino acid composition has an integer close to one for lysine which could 
possibly be the previously observed lysine. 
b) Cystine, cysteine, tyrosine and isoleucine are not present. It is 
believed that the determined isoleucine could be leucine. 
The value of glycine is very difficult to account for; it is most probably 
a high level of contamination. The amino acid region of the albumin was 
215 - 241 or 216 - 242 compared on both known sequences by Meloun et al and 
Behrens et al. The region (residues 216 - 242) seems the most likely 
because of the presence of a single histidine which is easily destroyed 
during irradiation. Some amino acids have been shown to be extremely 
susceptible to destruction by light and hence may account 
fo some values 
which do not tally. Histidine, threonine, arginine, phelylalanine, serine 
and tyrosine are amongst the easily destructible ones. 
However, conclusive evidence can only be made if the amino acid sequence 
of the peptide is made. Furthermore amino acid analysis alone does not 
clearly show which amino acid residue(s) have been modified. Perhaps 
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mass spectra studies on the peptide would have further elucidated the 
exact nature of the modification. It will suffice to speculate that 
cysteine residues might have been added to bilirubin to give an adduct 
unknown compared to the standards used. Ideally, the amino acid 
sequence of the peptide shown be known since commonly used conditions, for 
example, constant-boiling HC1 (ca. 5.7M) is used to hydrolyze a protein 
in vacuo at 110'C for 24 hours, the amounts of aspartic acid, serine, 
threonine, glutamic acid, valine, isoleucine, tyrosine, methionine 
tryptophan, cysteine and cystine present in the hydrolysate may be 
different from the amounts in the protein (peptide) hydrolyzed. 
The purity of the peptide had been judged as, homogenous by end 
group analysis, column and paper chromatography, then dialyzed against 
O. 1M NaCl to displace other salts and the salt subsequently removed by 
dialyzing against distilled water until no chloride ions could be 
detected with AgNO3 in the outer solution. 
Table 3: 2 shows figures in brackets which have been standardized 
using Arginine as the standard. The corresponding residues are given 
from the albumin. Many differences do exist between the peptide and the 
albumin especially with praline, glycine and alanine. There is no 
feasible explanation for the differences in praline and albumin except 
that they may not be involved in the binding and hence destroyed by 
irradiation. 
Jo. 
Chapter 4 
4: 1 Introduction 
In the breakdown of haem to its final products in the urine and faeces, 
several intermediate compounds of unknown physiological importance exist. 
Mesobilirubin is one of these compounds. Chemically, mesobilirubin is 
obtained from bilirubin by a catalytic hydrogenation of the vinyl groups 
to the ethyl groups. In the d series, therefore, mesobilirubins would 
be expected from bilirubin - III, XIII and IX (A , although the IX o1' is 
likely to exist in excess over the other two. Very little, however, is 
known of mesobilirubin due apparently to its non-causative nature. Unlike 
bilirubin, it has little or no association with neonatal jaundice as a 
result investigators have paid little attention to the chemistry of this 
pigment. One reason perhaps is that isolated investigators have recorded 
or shown the existence of mesobilirubin in the bile, 
55,57,238 
which they 
believed is produced extrahepatically by cellular enzymes. Using a cystine- 
bilirubin-peptone culture, Baumgartel54 was able to isolate mesobilirubin 
and concluded that it was an intermediary product of bacterial reduction of 
bilirubin. It is true, however, that like bilirubin, mesobilirubin has 
to be conjugated before excretion. 
Perhaps the most disturbing thing is that the common diazo reaction on 
serum bilirubin does not different between mesobilirubin and bilirubin. 
80 
This method has been used to determire bilirubin in the basal ganglia in the 
icteric newborn. Furthermore, in. vitro studies showed that bilirubin was 
reduced to mesobilirubin on adding basal ganglia. 
59 This may suggest an 
enzyme catalysed reaction or further support the idea of bacterial reduction. 
56,58 
In similar experiments Vogel extracted a kernicteric pigment with chloroform 
from the brains of infants. This pigment gave a positive diazo reaction 
and had a maximum absorption at 425 nm being identical in these properties 
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with chloroform solutions of crystalline mesobilirubin. 
80 
Vogel further 
induced experimental kernicterus by injecting solid mesobilirubin intra- 
cerebrally in newborn kittens and the pigment stained the tissue a bright 
canary yellow. Besides deeply jaundiced individuals have no bilirubin in 
their cerebral tissues. 
60 
A rather significant observation was that mesobilirubin binds to 
human serum albumin. 
81 Although this was a quantitative approach, it 
further confirms the possibility that mesobilirubin like bilirubin exists 
in the bile and may be transported by HSA. Fischer237 suggested that 
mesobilirubin may not be conjugated which if true would suggest, depending 
on the site of formation, that it may be more polar than bilirubin. In 
chloroform, bilirubin has a maximum absorption at 450nm and mesobilirubin 
at ca. 434 - 440 nm. Unconjugated mesobilirubin was determined in 
concentrations as low as 0.06mg/l00mL from the serum using the chloroform 
239,240 
extraction method. 
Bilirubin is a powerful metabolic poison in vitro systems. Therapy 
is directed towards preventing accumulation of bilirubin in excess of the 
infants' plasma binding capacity resulting in hyperbilirubinemia and 
kernicterus. On the contrary no clear evidence exists to disapprove the 
possibility of mesobilirubin being the kernicteric pigment. 
241 
It is 
therefore necessary to determine whether mesobilirubin actually binds to 
human serum albumin. Labelled mesobilirubin and bilirubin were poorly 
excreted by Gunn rats (8%) than by normal rats (76%). In contrast 
mesobilirubinogen was excreted readily by both rats. This is in contrast 
with Fischer's237 suggestion that mesobilirubin is more polar than bilirubin. 
The pattern of excretion of mesobilirubin was found to be strikingly similar 
to that of bilirubin. 
242 It is therefore tempting to assume that 
mesobilirubin and bilirubin may share the same secretory carrier. The 
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change of the vinyl groups to ethyl groups does not influence the 
"fit" of the tetrapyrrole to the secretory carrier. 
Catalytic hydrogenation of bilirubin in 0.1M NaOH in the 
presence of palladium (Pd) catalyst was first introduced by Fischer 
and coworkers. 
243 
The stepwise process of this reaction produces 
mesobilirubinogen as the end product. By contrast, hydrogenation 
of bilirubin with sodium amalgam in NaOH did not proceed in a stepwise 
manner, and only mesobilirubinogen was isolated. 
243 Another method 
of bilirubin reduction in methanol/ ammonia in the presence of Pd/C 
proceeded mainly to mesobilirubin. 
243 
Thus depending on the solvent 
or solvent systems various intermediates of the bilirubin reduction 
can be obtained. 
4: 2 Synthesis of mesobilirubin from bilirubin244 
Bilirubin (200mg) was dissolved in methanol/ammonia (200 mL). 
This solution was then added to the suspension of a catalyst, Pd/C 
(10%) (200 mg). Hydrogenation was allowed to proceed for 1-2 hours 
at 19'C. The catalyst was filtered off and washed with the same 
solvent (100mL) used in the reduction. The final solution was 
poured into petroleum ether (2 litres) and concentrated to about 
100 mL. Then sufficient chloroform (50 - 100 mL) was added for 
extraction. All the chloroform extracts were pooled, dried with anhydrous 
sodium sulphate and concentrated to about 5.0 mL. Mesobilirubin was 
crystallized from CHC 13/acetone and then from methanol/ethyl acetate_ 
Yield = 132.7 mg (66.4%) 
x max in chloroform = 434 - 435 nm. 
M. p. = 315 - 3180C 
Calculation of £, 
Mesobilirubin (0.6mg) was dissolved in chloroform (100 mL). 
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Fig. 29. U. V. spectra of mesobilirubin and albumin- 
mesobilirubin complexes. 
1 denoted the spectrum of mesobili_rubin 
alone in sodium phosphate buffer, pH 7.4, 
0.1M. 
2 denotes the spectrum of mesobi_ltrubi_n- 
albumin complex in the molar ratio of 1: 1. 
3 denotes the spectrum of mesobilirubin- 
albumin complex in the molar ratio of 2: 1. 
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This solution had an absorbance of 0.58 in a cuvette of 1 cm path 
length. 
A =EC1 
:. E=A 
C1 
The molecular weight of mesobilirubin is assumed to be 588.7. The 
concentration of the solution is: 
6mg/1 
i. e. 6.0/588.7 M 
= 1.02 x 10-5M 
Hence E=0.58 = 56,900 M-1 cm-1 
1.02 x 10-5M x lcm 
Table 4: 1 
Experiment Literature239 
max 434 - 435 434 nm 
E 56,900 56,000 
M. P. 315 - 318'C 315'C 
4: 3 Binding studies of mesobilirubin to HSA 
4: 3: 1 Spectroscopic studies: 
A stock solution of mesobilirubin was made by dissolving 1.40 mg 
in O. 1M NaOH (0.2 mL) and diluted to 100 mL with 0.1M sodium phosphate 
buffer, pH 7.4. Albumin solutions were prepared to give the final 
molar ratios of 1.0 and 2.0 with respect to mesobilirubin. Mesobilirubin 
in aqueous solution, (pH 7.4), had a maximum wavelength at 410 - 412 nm; 
this shifted to 438 - 440 nm on addition of albumin (Figure 29). This 
bathochromic shift is characteristic of the binding of most ligands to 
macromolecules. The measurements were done on a Cecil 505 Double Beam 
UV Spectrophotometer using the buffer as the reference. 
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4: 3: 2. Fluorescent studies: Done according to, Levine. 
245 
Bilirubin alone does not fluoresce yet it does when added to 
albumin. The latter fluoresces due to its aromatic residue especially 
tryptophan. However, human serum albumin does not fluoresce very 
much with its single tryptophan residue compared to bovine serum 
albumin. Binding studies can be performed therefore either by 
enhancing or quenching the fluorescence of the albumin by mesobilirubin 
which like bilirubin does not fluoresce alone. 
Experimental: 
A fresh stock solution of mesobilirubin was made by dissolving 
5.0 mg in 0.1 M NaOH (0.2 mL) and diluted to 5.0 mL with 0.1M sodium 
phosphate buffer, pH 7.4 in 0.1mM EDTA to give a 1.70 x 10 _M solution. 
Albumin stock solution was determined by measuring the absorbance 
at 280 nm and using Elcm = 5.3. With the molecular weight of 66300, 
a stock solution of 1.70 x 10_4M was made up in the same buffer. 
The working solutions for mesobilirubin were 2.02 x 10-5M and 
2.028 x 10-4M and those for albumin were 1.01 x 10-6M and 
1.014 x 10-5M respectively. To the working mescbilirubin solutions 
was added albumin in 20: 1 ratio before titration. This was done (a) 
to prevent the dilution of titrated albumin and (b) to stabilize the 
mesobilirubin. 
Three 4mL - cuvettes were used; one filled with the buffer and 
the other two with albumin (2.0 mL). The latter two were arbitrary 
designated reference and titration cuvettes. The cuvette containing 
the buffer was used to set the zero or blank fluorescence, and the 
reference cuvette to set 1.0. The fluorescence of the titration 
cuvette was then read on a Perkin Elener MPF -3 Fluorescence 
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Fig. 30. Plot of observed fluorescence 
against mesobilirubin-albumin ratios. 
The albumin concentration was 1. OluM. 
Fig. 31. Plot of observed fluorescence 
against mesobilirubin-albumin ratios. 
The concentration of albumin was 10.1u1. 
The quenching effect is clearly observed at 
albumin concentrations of 1. OluM than at ten 
times more. 
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Spectrofluorimeter at about 24*C. The reference cuvette helped to 
check the drift in the fluoremeter response, variation in intrinsic albumin 
fluorescen.. re z"nd any fluorescence due to the buffer. Measurements were 
done using the different concentrations of mesobilirubin with the 
respective albumin concentrations. 
5 or 10 uL of the mesobilirubin solution was added to the titration 
cuvette with a Hamilton microsyringe. The solution was mixed by 
inversion of the cuvette, and fluorescence was measured. About 20 - 35 
aliquots were found to be necessary in both cases. The shLItter 
allowing light to strike the test solution was opened only when reading 
fluorescence. This precaution avoided significant photodecomposition 
of the mesobilirubin. 
The excitation wavelength used was 294 nm and emission was 343 nm, 
with the half band, width of 13 nm. A control experiment which was 
performed by adding the buffer to the albumin showed that all the quenching 
was due to the ligand (mesobilirubin). At the end of the experiment 
the absorbance of the titrated solution was read at 294 nm and 343 
against the albumin solution. The molar absorptivity calculated from 
this was used to correct for the inner filter effect. 
Results and Discussion 
The correction due to inner filter effect was calculated as follows: 
Fcorrected Fobserved XH 
where 
H= antilog (E +E)x (mesobilirubin) (pathlength, cm) excitation emission 2 
which becomes 
H= antilog (E excitation = 
Eemission )x (mesobilirubin) (0.4) 
Figures 30 and 31 show plots of fluorescence observed (Fobs. ) against 
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Fig. 32. Plot of relative fluorescence against 
mesobilirubin/albumin molar ratios. 
Albumin concentration 1. OluM. 
Fig. 33. Plot of relative concentration apainst 
mesobilirubin/albumin molar ratios. 
Albumin com6entration 10.1uM 
The relative fluorescence had been corrected or 
inner filter effect. 
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mesobilirubin/albumin ratio Q, for the 1.01 uM and 10.1 uM albumin 
solutions respectively. In the Figures 32 and 33 are plots showing 
the corrected fluorescence (Fcorr) against the mesobilirubins/albumin 
ratio (Q). Plots of albumin concentrations less than 1.0 uM (not 
shown) were erratic perhaps due to light scattering by colloidal 
formation of mesobilirubin at such low albumin concentrations. The 
effect of the total amount of protein compared to the quenching can be 
observed by comparing Figures 32 and 33. When the albumin concentration 
was 1.01 x 10-6M, the intrinsic fluorescence of the albumin was quenched 
to approximately 50% by mesobilirubin. This phenomenon is not clearly 
5 
illustrated in the 1.01 x 10 M solution of albumin (Figure 33). 
After a mole of mesobilirubin is bound, no more quenching is observed 
and the plot of fluorescence (Fcorr) against the molar ratio of 
mesobilirubin to albumin levels off. This phenomenon is not observed 
in the HSA/bilirubin complexes in which the first three bilirubins to 
bind to HSA have the same or yield about the same fluorescence. The 
first mesobilirubin has this anomalous nature of quenching the fluores- 
cence without causing a further decrease in the albumin fluorescence. 
It appears that concentrations of albumin in the range of 10-5M 
are not suitable for binding studies. The binding of mesobilirubin is 
accompanied by a loss in protein-intrinsic fluorescence. Because of 
the strong absorption of mesobilirubin in the region of protein emission, 
the most likely-explanation of the quenching is resonance energy 
transfer from the excited tryptophan to mesobilirubin. 
Calculations: 
The Scatchard plot (Figure 34) shows that the human serum albumin 
has two association constants for mesobilirubin i. e. K, = 6.15 x 106M-1 
6 
and K2 = 0.88 x 10 M- 
1 
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Fig. 34. Scatchard plot of the binding of mesobilirubin 
to albumin in sodium phosphate buffer, pH 7.4, 
ionic sttength O. 1M, at 24'O'C. Q is the 
average number of moles of mesobilirubin bound 
to albumin, and R is the ratio for maximal 
quench. 
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The resulting calculations according to Levine 
244 
are based on the 
following: 
R is the molar ratio of mesobilirubin to albumin at maximal 
quench. 
F0 is the fluorescence of albumin alone and Fl is the fluorescence 
due to the quenching of albumin by mesobilirubin at a molar ratio of 
one. 
The observed fluorescence, F, is given by the equation: 
F= F0 - M, R 
and 
F1 = Fo -M when R=1.0 
The maximal quench is therefore given by 
F0 - Fl = Ml. 
Q, is the average number of moles bound to albumin given by 
F- F/m. 
0 
The high affinity binding of mesobilirubin (Ka = 6.15 x 106M-1) 
compares very well with the weaker binding site of bilirubin 
(Ka = 0.6 x 106M-1). Its weaker binding site is a magnitude of 
seven less than the high affinity site. The concentrations of albumin 
used was constant at 1.01 x 10-6M which was found to be in the region 
favourable for most fluorescence experiments. 
Mesobilirubin, like bilirubin does not fluoresce in certain organic 
solvents and water. But when bound to albumin it shows some slight 
fluorescence. This extrinsic fluorescence is a measure of the bound 
mesobilirubin undergoing slow transformation. This change like that 
in bilirubin may involve a considerable entropy change. Studies at 
different temperatures would therefore be necessary to confirm this. 
During these studies it was observed by UV spectrophotometry that although 
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albumin/mesobilirubin complexes bind bilirubin, the albumin/bilirubin 
complexes did not. This is further confirmation that tighter binding 
occurs with bilirubin than with mesobilirubin. Table 4.2 shows the 
comparison of properties of mesobilirubin and bilirubin: 
Table 4.2 
Property Mesobilirubin Bilirubin246 
max in CHC13 (nm) 435 453 
in sodium phosphate 
buffer, pH 7.4,0.1M ca 412 438 
with Albumin 438 460 
Association Constants: 
k1 6.15 x 106M-1 
+ 7.0 X 107M-1 
k2 0.88 x 106M-1 0.6 x 107M-1 
Solubility: 
CHC13 Yes Yes 
DMSO Yes Yes 
0.2M Na2CO3 Yes Yes 
Methanol No No 
Na OH Yes Yes 
Diazo reaction Positive Positive 
Excretion Conjugation Conjugation 
+ Measurements done by fluorescence at 24'C for Mesobilirubin and 
25' for Bilirubin, pH 7.4. 
Mesobilirubin is one of the intermediates in the catabolism of bilirubin 
to urobilin and stercobilin. Previous studies have shown the pigment 
to be found in the bile; and although its physiological role is yet 
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unknown, its appearance in the bile surely raises some questions. 
It may probably be that an enzyme system(s) exist(s) in the liver or 
kidney that reduces the vinyl groups to ethyl groups. The fact it 
is less tightly bound to albumin may imply a different carrier al- 
together. However, Goto (1956) showed that albumin binds mesobilirubin 
using paper electrophoresis. Despite all these observations all the 
"credit" went to bilirubin and investigators have since ignored the 
possibility that mesobilirubin could be as cytotoxic as bilirubin. 
This argument is supported by lack of bilirubin in deeply jaundiced in 
individuals; 
60 
mesobilirubin was found as the kernicteric pigment 
in the basal ganglia of infants. 
80 Many products of phototherapy 
in vivo are still unknown, it would be possible to speculate that 
some of these products are from mesobilirubin. Furthermore mesobili- 
rubin was shown to produce photo-oxidation products such as 
methyethylmaleimide. 
155 Indeed the synthesis of mesobilirubin is 
solvent dependent but in vivo synthesis could follow a different 
method altogether. Evidence exists as to the possibility of the same 
carrier in the plasma since labelled mesobilirubin and bilirubin were 
excreted at more or less the same time by normal rats. To circumvent 
this problem entails the improvisation of a method that would clearly 
distinguish. mesobilirubin from bilirubin in the serum and the jaundiced 
sites. 
Clinically, therefore resorption of mesobilirubin by the hepatic 
system could cause some displacement or competition. at the weaker sites 
for bilirubin binding. However, since this phenomenon has not been 
recorded or observed, it is possible that some bile constituent quickly 
reduce mesobilirubin to other products. If, however, the weaker 
80. 
binding site of bilirubin is the same as the high affinity for 
mesobilirubin, then the latter pigment could be used to study the 
topography of this site. If this speculation is correct it would 
serve the problem of using bilirubin which would not be a better probe 
for its secondary sites because of the existence of tighter binding 
sites. 
The existence of mesobilirubin in the ganglia is obviously 
worth following. Unconjugated bilirubin not bound to albumin will 
not cross the brain-blood barrier, yet there have been suggestions that 
it may cross and then be reduced to mesobilirubin by the basal ganglia. 
59 
This is further complicated by lack of a clear definition of the blood- 
brain barrier. It is also possible that mesobilirubin existing in 
little quantities in the serum can cross the barrier. Although there 
is no supportive evidence to this; but it is known that anemia, 
247 
248 248 249 
anoxia, immaturity, hepatic toxins and the toxic effects of 
bile pigments250 are factors that may influence the permeability of 
the blood-brain barrier to a degree that would allow bilirubin to pass 
from the blood stream into the cerebral tissues. It was also shown 
that intact neurons take abundant mesobilirubin without the former 
exhibiting cytological changes, 
251 
but whether this is a short or long 
term effect Is not known. This observation may be likened to the 
influence on the hepatic uptake of bilirubin by ligandin in the liver. 
It is possible that mesobilirubins by some yet unknown factor "drains" 
into the neurons which are likely to have a strong affinity for the 
pigment. The brain contains significant amount of sphingomyelin 
(SPH) with an association constant of 4.0 x 106M-1 for bilirubin. 
251 
It is believed that this very high association of SPH (compared to other 
lipids) may allow tying up very low levels of unconjugated bilirubin 
81. 
or weak binding bilirubin from serum albumin, or the so-called free 
bilirubin in patients with high serum concentration of unconjugated 
bilirubin. This may be one of the possibilities for bilirubin toxicity 
in the brain. 
25 The toxicity becomes evident only when all the SPH 
molecules (in membrane as well) are tied up. It is necessary to recall 
that Vogel80 observed that for a certain period mesobilirubin 
accumulated on to the neuron without causing any noticeable cytological 
changes. It is therefore possible that like in the case of SPH, 
252 
certain mesobilirubin binding factors within the neuron have to be 
saturated before any toxicity is evident. 
Most of these phenomena are likely due to the strong association 
constant of specific lipids within the affected systems for the bile 
pigments. Since association constants of mesobilirubin with such lipids 
as SPH are not known it will suffice to speculate that from the little 
evidence available, mesobilirubin is a possible candidate for some of 
the neurological disorders currently attributed to bilirubin. 
The binding studies of mesobilirubin have confirmed the 
importance of vinyl groups to the binding of albumin. A comparison 
of the high affinity association constants (Table 4.2) reveals that 
bilirubin is bound 11 times more strongly than mesobilirubin. If 
mesobilirubin is not as poisonous as bilirubin, then it is advantageous 
for the body to convert the latter pigment to the former. 
4.4. Conclusion: 
It goes without saying that the study of the binding of endogenous 
and exogenous substances to macromolecules will remain a field of 
interest to clinicians, pharmacologists and biochemists. Organic 
anions, like bilirubin and mesobilirubin can be used as probes to study 
certain phenomena likely to be exhibited by identical compounds within 
82, 
the transport milieu. The results from the present studies of 
bilirubin can only afford a hypothetical explanation as to the binding 
site and the mechanism of phototherapy. More light can be expected 
from other approaches of mass spectra studies, kinetics of the formation 
of photoproducts of phototherapy, peptide mapping, analysis of the 
nature of intermediate products of phototherapy, etc. With an 
improved method of labelling bilirubin to high specific activity and 
consequently labelling the albumin, and the increasing task force of 
protein chemists now interested in bilirubin binding, it may not be 
long before the knowledge on the mechanism of bilirubin binding is 
complete. It is hoped that the present studies on mesobilirubin will 
further stimulate the need to study the chemistry and effect of this 
pigment whose mere similarity and derivation from bilirubin has 
militated against the study of its existence in the basal ganglia 
and serum. 
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Appendix I 
Charcoal Treatment of HSA with some modifications: 
The treatment was done according to Chen, R. F. (1967), 242, 
173 
J. Biol. Chem. 
Albumin (10g) was dissolved in 100 mL of distilled water at 24'C. 
Charcoal Norit -A (5.0g) was added and the mixture lowered to pH 3.0 
by adding 0.2M HC1. The solution was then placed on an ice bath 
and mixed magnetically for 1 hour. Charcoal was removed by 
centrifu. gation at 20,000 xg for 20 minutes in a Sorvall RCl centrifuge 
with an 55 34 Rotor at 20. The solution was further put on Sephadex 
G- 10 (0.6 x 60cm) and eluted with distilled water. This column 
was found to remove fines from charcoal which did not sediment 
during centrifugation. The clarified albumin was adjusted to 
pH 7.0 by addition of 0.2M NaOH 
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Source of Materials 
C arboxymethy cellulose (CM) Whetman Ltd., Maidstone, Kent. 
Cyanogen bromide Eastman Kodak Co., Rochester, 
N. Y. 
Dansyl Amino Acids Standards Sigma, London 
Dansyl Chloride Sigman, London 
DEAE - cellulose 
Whatman Ltd., Maidstone, Kent. 
N-ethylmorphiline B. D. H. Chemicals, Ltd., Poole, 
Dorset. 
PM - 10 membranes Amicon Corporation, Lexington, Mass., U. S. A. 
Sephadex G-25 Pharmacia Fire Chemicals, 
Sweden. 
Sephadex G-100 Pharmacia Fire Chemicals, 
Sweden. 
Sephadex G-10 Pharmacia Fire Chemicals, 
Sweden 
Sepharose 4B Pharmacia Fire Chemicals, 
Sweden 
Bilirubin Sigman, London 
Pepsin Worthington B iocchemicals, 
Freehold, New Jersey. 
Polyamide Layer Sheets E. Merck, Darmstadt. 
Silica gel plates E. Merck, Darmstadt. 
Tritiated Water E. Merck, Darmstadt. 
H. S. A. Sigma, London 
10% Palladium/Charcoal Johnson Matthey Chem. Ltd., 
London, England 
n-Bu: yllithium Aldrich Chem. Co., Gillingham, 
Dorset 
Di-isopropylamine Aldrich Chem. Co., Gillingham, 
Dorset 
Hexamethylphosphoric triamide Aldrich Chem Co., Gillingham, 
Dorset. 
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Photoactivated Covalent Binding of ['H]Bilirubin to Human Serum Albumin 
By David W. HUTCHINSON and David S. MUTOPO 
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A one-step procedure has been developed for the preparation of ['H]bilirubin IX-a in 
good yield from unlabelled bilirubin. Irradiation of an aqueous solution of [3H]bilirubin 
IX-a in the presence of human serum albumin results in the covalent attachment of the 
bilirubin to the protein. Preliminary degradation studies have been carried out to locate 
the site of attachment of the bilirubin to the albumin. 
Bilirubin is reversibly bound to serum albumin in 
plasma and is transported to the liver where it is 
conjugated and then excreted. Many experiments 
have been aimed at locating which domain of the 
albumin molecule binds bilirubin, but no conclusions 
have yet been made as to the exact site of binding. For 
example, affinity labelling of human albumin with 
bilirubin that had been activated with Woodward's 
reagent K (2-ethyl-5-m-sulphophenylisoxazolium 
hydroxide) (Gitzelmann-Cumarasamy et a!., 1976; 
Kuenzle et a!., 1976) indicates that two regions 
(residues 124-297 and residues 446-547) are attached 
to the bilirubin. However, objections can be raised to 
the activation of bilirubin by this reagent as the latter 
interacts initially with the carboxy groups of the 
bilirubin and for covalent attachment a suitably 
nucleophilic amino acid side chain of the albumin 
must be present in a favourable position in the binding 
site. Thus purely hydrophobic interactions between 
the albumin and the bilirubin are unlikely to be 
revealed by this method. 
In the present paper we report the photoactivated 
covalent binding of ['H]bilirubin to human serum 
albumin. This activation, which is brought about by 
light from a tungsten lamp, presumably involves free 
radicals and may not require the presence of nucleo- 
philic groups in the binding site before a covalent 
attachment of the bilirubin to the albumin can occur. 
Thus this technique may reveal amino side chains 
that are involved in hydrophobic bonding to the 
bilirubin. 
Materials and Methods 
n-Butyl-lithium, di-isopropylamine and hexa- 
methylphosphoric triamide were obtained from 
Aldrich Chemical Co., Gillingham, Dorset, U. K., and 
CNBr was obtained from Eastman Kodak Co., 
Kirkby, Liverpool, Lancs., U. K. Bilirubin IX-a and 
human serum albumin (fraction V) were obtained 
from Sigma (London) Chemical Co., Kingston upon 
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Thames, Surrey, U. K. The albumin was defatted 
before use by the method of Chen (1967). 
Synthesis of ['Hjbilirubin 
To a solution of di-isopropylamine (0.2g, 2. Ommol) 
in anhydrous tetrahydrofuran (80ml) under an N2 
atmosphere was added n-butyl-lithium in hexane 
(1.0ml, 1.6M) and the mixture was stirred at -78°C 
for 30min. Bilirubin (58.4mg, 0.1 mmol) was added 
and the mixture was stirred at -78°C for 30min after 
which hexamethylphosphoric triamide (1.5 ml, 
8.55 mmol) was added. The mixture was stirred for a 
further 30min and then trifluoro[3H]acetic acid 
(0.546m1,4.8mmol) was prepared by treating tri- 
fluoroacetic anhydride with an equimolar amount of 
'H2O (5Ci/ml; sp. radioactivity approx. lOOmCi/ 
mmol). The reaction was stirred for 4h at 21°C and 
then acidified with 0.1 M-HCI at 0°C. The aqueous 
solution was extracted with chloroform (3 x 100 ml), 
the chloroform extracts were combined, dried 
(Na2SO4) and evaporated to dryness in vacuo. The 
residual bilirubin was dissolved in chloroform (5 ml) 
and purified by preparative t. l. c. on silica gel with 
chloroform/methanol/water (40: 9: 1, by vol. ) as 
solvent. The yellow band (RF 0.75) was excised and 
eluted from the silica with chloroform. The chloro- 
form was removed in vacuo and the residual bilirubin 
was crystallized from chloroform/methanol (1: 1, v/v) 
to yield 19.5 mg. This bilirubin was then suspended in 
water and brought into solution by adding sufficient 
conc. aq. NH3 (sp. gr. 0.88). After 5min the solution 
was acidified with 1 mM-HCI and extracted with 
chloroform (100ml). The chloroform was dried 
(Na2SO4) and evaporated in vacuo to give ['H]bili- 
rubin (19.3 mg, 33 % yield from unlabelled material). 
The bilirubin ran as a single spot on t. l. c. (McDonagh 
& Assissi, 1971), had a light-absorption maximum in 
chloroform at 454 nm (e59650 litre " mol-' . cm-1) and 
had a sp. radioactivity of 1.3mCi/mmol. Diazoti- 
zation (Hutchinson et al., 1972) of the ['H]bilirubin 
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gave azopigments with at least 99 % of the specific 
radioactivity of the bilirubin. 
Covalent binding of ['H]bilirubin to human serum 
albumin 
A solution of ['H)bilirubin (65tpM) was prepared 
by dissolving 3.8 mg (sp. radioactivity 1.3x l0' 
c. p. m. /mmol) in 0.2M-NaOH (0.2ml) and diluting to 
100ml with 0.1 M-sodium phosphate buffer, pH 7.4. 
A mixture of this solution (5ml) and a solution of 
human serum albumin (5 nil, 65µM) in 0.1 M-sodium 
phosphate buffer, pH7.4, was irradiated at 40cm 
from a tungsten lamp (150 W) for 1 h. 
The reaction mixture was then applied to a column 
(0.90cmx 15.0cm) of Sepharose-albumin (Kuenzle 
et al., 1976). The column eluate was dialysed against 
2 litres of 12.5 mm-sodium salicylate, pH 7.4, for 48 h 
and then against 2 litres of 0.1 M-HCI for 24h, after 
which time a non-diffusible bitirubin-albumin 
complex (5 x 10' c. p. m. /minol of albumin) was ob- 
tained. In a typical experiment, after irradiation for Ih 
a solution of albumin (5.0mg/ml) had an absorption 
of 0.50 at 450nm after chromatography on Sepharose- 
albumin. When the experiment was repeated with 
degassed solutions and with NZ flushing during the 
irradiation, the residual specific radioactivity was 
virtually the same. If the irradiation step was omitted 
the specific radioactivity of the bilirubin-albumin 
complex was 2x l0" c. p. m. /mrnol of albumin. 
Degradation of hi/irubin-albumin complex by CNBr 
The bilirubin-albumin complex was dissolved in 
formic acid and degraded with CNBr (McMenamy 
1). W. HUTCHINSON and D. S. MU"IOPO 
et al., 1971). After chromatography, three peptides 
were obtained [A (residues 298-585), B (residues 
1-124) and C (residues 125--297)], the identities of the 
peptides being confirmed by the determination of 
their N-terminal amino acids. For the complex 
obtained after irradiation for 60min in the air, the 
maximum radioactivity (62 ) was found in peptide B 
with lesser amounts in peptides C (32 ", ('; ) and A (3%). 
When the albumin obtained from the non-irradiated 
sample was degraded with CNBr no radioactivity 
could be detected in any of the peptides. 
Discussion 
Treatment of the lithium derivative of aceto- 
phenone with trifluoro['H]acetic acid has been de- 
scribed recently as a method for the synthesis of 
[2-3[1]acetophenone in high yield, the latter being 
used for the preparation of phenyl[2-'H]glyoxal 
(Augustus & Hutchinson, 1979). We have now 
adapted this method for the one-step preparation of 
[3H]bilirubin from unlabelled material. This method 
is preferable to the two-step procedure involving the 
preparation of bilirubin dimethyl ester (Hancock et 
at., 1976) as the overall yield is higher and the specific 
radioactivity of the [3H]bilirubin obtained is greater. 
By analogy with other reactions of metallated 
carboxylic acids (Creger, 1977), we assume that only 
one 3H atom is introduced into each a-methylene 
group of the bilirubin. No 3H is introduced into the 
bridge methylene group as diazotization of the 
[3H]bilirubin yields azopigments that contain at least 
99% of the initial radioactivity. 
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Irradiation of a mixture of [3H]bilirubin together 
with one molar equivalent of human serum albumin 
with light from a tungsten lamp resulted in the 
bilirubin becoming firmly bound to the protein. 
Flushing the reaction mixture with N2 before and 
during the irradiation did not have an appreciable 
effect on the amount of radioactivity that is firmly 
bound to the albumin. This suggests that either the 
binding is not an oxidative process, but may involve 
the addition of an amino acid side chain of the albumin 
to one or both of the exo-vinyl groups of the bilirubin 
(Manitto & Monti, 1972), or that trace amounts of 02 
remaining in the system are sufficient to allow the 
photo-oxidation of bilirubin to take place (Bonnett, 
1976). The photo-activated bilirubin could then react 
with an amino acid side chain in the albumin mol- 
ecule. The relative concentrations of albumin and 
bilirubin in these preliminary experiments were 
chosen so that high-affinity binding site in the albumin 
is just fully occupied. Thus it is hoped that compli- 
cations due to the binding of bilirubin at high- and 
low-affinity sites do not arise to a significant extent. 
We have found that it is difficult to remove final 
traces of radioactive bilirubin from the albumin even 
when no irradiation has taken place. A combination 
of chromatography on an affinity column of human 
serum albumin-Sepharose (Kuenzle et a!., 1976) and 
exhaustive dialysis against sodium salicylate and 
0.1 M-HCI failed to remove the final traces of radio- 
activity. However, the covalent attachment of 
bilirubin to the albumin after irradiation could be 
clearly demonstrated by degradation of the latter 
with CNBr (McMenamy et a!., 1971). No radio- 
activity was associated with the degradation products 
unless irradiation of the bilirubinralbumin mixture 
had taken place. 
The majority of the radioactivity (62 %) is asso- 
ciated with the peptide corresponding to residues 
1-124 and 32% was associated with residues 125-297. 
This contrasts with the observations of Gitzelmann- 
Cumarasamy et al. (1976), who found that two regions 
in the albumin (residues 124-297 and 446-547) 
become bound to the bilirubin. This difference may 
be due to the difference in manner in which the 
bilirubin is activated. After activation with Wood- 
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ward's reagent K, the carboxy groups of the bilirubin 
may be unable to react with any amino acid side 
chains in the binding site, but may react with nucleo- 
philic groups that are remote from this site. Alterna- 
tively, in our experiments the ZZ-isomer of bilirubin 
IX-a may undergo a configurational change during 
irradiation to one of the three other geometric isomers 
of bilirubin IX-a (McDonagh et a!., 1979) before 
reaction with the albumin takes place. We have been 
unable to detect chromatographically the formation 
of other isomers of bilirubin, e. g. the III-a or XIII-a 
isomers, during our irradiation experiments. It is 
relevant that Geisow & Beaven (1977) found that 
bilirubin bound non-covalently to two albumin- 
derived peptides corresponding to residues 1-386 
and 49-307 respectively. 
Further experiments are required to investigate the 
nature of the binding reaction and to locate exactly 
the site of attachment of the bilirubin to the albumin. 
We thank the United Nations for financial support 
(D. S. M. ). 
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